WO2023031779A1 - Compositions, kits, and methods to provide synergistic and/or additive effects from comprised ingredients for the prevention, treatment and management of nausea and vomiting - Google Patents
Compositions, kits, and methods to provide synergistic and/or additive effects from comprised ingredients for the prevention, treatment and management of nausea and vomiting Download PDFInfo
- Publication number
- WO2023031779A1 WO2023031779A1 PCT/IB2022/058102 IB2022058102W WO2023031779A1 WO 2023031779 A1 WO2023031779 A1 WO 2023031779A1 IB 2022058102 W IB2022058102 W IB 2022058102W WO 2023031779 A1 WO2023031779 A1 WO 2023031779A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- salt
- pharmaceutical composition
- ginger
- phosphate
- nausea
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 105
- 238000000034 method Methods 0.000 title claims abstract description 51
- 239000004615 ingredient Substances 0.000 title claims abstract description 49
- 206010047700 Vomiting Diseases 0.000 title claims description 99
- 238000011282 treatment Methods 0.000 title claims description 64
- 230000002265 prevention Effects 0.000 title claims description 27
- 230000002195 synergetic effect Effects 0.000 title abstract description 8
- 230000000996 additive effect Effects 0.000 title abstract description 7
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 122
- 235000008397 ginger Nutrition 0.000 claims abstract description 122
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims abstract description 85
- 239000000739 antihistaminic agent Substances 0.000 claims abstract description 62
- 230000001624 sedative effect Effects 0.000 claims abstract description 60
- 239000000932 sedative agent Substances 0.000 claims abstract description 59
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims abstract description 41
- 230000001387 anti-histamine Effects 0.000 claims abstract description 41
- 241000234314 Zingiber Species 0.000 claims abstract 3
- 150000003839 salts Chemical class 0.000 claims description 123
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 claims description 80
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 claims description 80
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 claims description 80
- 239000008194 pharmaceutical composition Substances 0.000 claims description 70
- 235000002780 gingerol Nutrition 0.000 claims description 60
- 239000003814 drug Substances 0.000 claims description 42
- 206010028813 Nausea Diseases 0.000 claims description 39
- 230000008693 nausea Effects 0.000 claims description 39
- 230000008673 vomiting Effects 0.000 claims description 37
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 claims description 34
- 239000011764 pyridoxine hydrochloride Substances 0.000 claims description 34
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 claims description 25
- 229960005178 doxylamine Drugs 0.000 claims description 24
- HCFDWZZGGLSKEP-UHFFFAOYSA-N doxylamine Chemical compound C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 HCFDWZZGGLSKEP-UHFFFAOYSA-N 0.000 claims description 24
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 claims description 22
- OQWKEEOHDMUXEO-UHFFFAOYSA-N (6)-shogaol Natural products CCCCCC=CC(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-UHFFFAOYSA-N 0.000 claims description 21
- OQWKEEOHDMUXEO-BQYQJAHWSA-N [6]-Shogaol Chemical compound CCCCC\C=C\C(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-BQYQJAHWSA-N 0.000 claims description 21
- -1 (lO)-gingerol Chemical compound 0.000 claims description 20
- 229960004993 dimenhydrinate Drugs 0.000 claims description 20
- MZDOIJOUFRQXHC-UHFFFAOYSA-N dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 claims description 20
- 229960003910 promethazine Drugs 0.000 claims description 20
- VRQVVMDWGGWHTJ-CQSZACIVSA-N methotrimeprazine Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1 VRQVVMDWGGWHTJ-CQSZACIVSA-N 0.000 claims description 18
- 229940042053 methotrimeprazine Drugs 0.000 claims description 18
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 16
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 claims description 16
- SOYKEARSMXGVTM-HNNXBMFYSA-N dexchlorpheniramine Chemical compound C1([C@H](CCN(C)C)C=2N=CC=CC=2)=CC=C(Cl)C=C1 SOYKEARSMXGVTM-HNNXBMFYSA-N 0.000 claims description 15
- 229960001882 dexchlorpheniramine Drugs 0.000 claims description 15
- 229960000520 diphenhydramine Drugs 0.000 claims description 15
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims description 15
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 claims description 15
- UVKZSORBKUEBAZ-UHFFFAOYSA-N cyclizine Chemical compound C1CN(C)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 UVKZSORBKUEBAZ-UHFFFAOYSA-N 0.000 claims description 14
- 229960003564 cyclizine Drugs 0.000 claims description 14
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 14
- 206010039897 Sedation Diseases 0.000 claims description 13
- 239000002207 metabolite Substances 0.000 claims description 13
- 230000036280 sedation Effects 0.000 claims description 13
- ZZHLYYDVIOPZBE-UHFFFAOYSA-N Trimeprazine Chemical compound C1=CC=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1 ZZHLYYDVIOPZBE-UHFFFAOYSA-N 0.000 claims description 12
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 claims description 10
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 10
- BCIWKKMTBRYQJU-INIZCTEOSA-N (8)-Gingerol Chemical compound CCCCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 BCIWKKMTBRYQJU-INIZCTEOSA-N 0.000 claims description 9
- 239000003963 antioxidant agent Substances 0.000 claims description 9
- 229940002508 ginger extract Drugs 0.000 claims description 9
- 235000020708 ginger extract Nutrition 0.000 claims description 9
- WHOMFKWHIQZTHY-UHFFFAOYSA-L pyridoxine 5'-phosphate(2-) Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(CO)=C1O WHOMFKWHIQZTHY-UHFFFAOYSA-L 0.000 claims description 9
- 229960004172 pyridoxine hydrochloride Drugs 0.000 claims description 9
- 230000001225 therapeutic effect Effects 0.000 claims description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- CZNLTCTYLMYLHL-UHFFFAOYSA-N [6]-Paradol Chemical compound CCCCCCCC(=O)CCC1=CC=C(O)C(OC)=C1 CZNLTCTYLMYLHL-UHFFFAOYSA-N 0.000 claims description 8
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000000651 prodrug Substances 0.000 claims description 8
- 229940002612 prodrug Drugs 0.000 claims description 8
- 235000008151 pyridoxamine Nutrition 0.000 claims description 8
- 239000011699 pyridoxamine Substances 0.000 claims description 8
- ZMJGSOSNSPKHNH-UHFFFAOYSA-N pyridoxamine 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(CN)=C1O ZMJGSOSNSPKHNH-UHFFFAOYSA-N 0.000 claims description 8
- 235000008974 pyridoxamine 5'-phosphate Nutrition 0.000 claims description 8
- 239000011580 pyridoxamine 5'-phosphate Substances 0.000 claims description 8
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 7
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 7
- 235000006708 antioxidants Nutrition 0.000 claims description 7
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 claims description 7
- 229960001140 cyproheptadine Drugs 0.000 claims description 7
- 239000011768 flavin mononucleotide Substances 0.000 claims description 7
- FVTCRASFADXXNN-UHFFFAOYSA-N flavin mononucleotide Natural products OP(=O)(O)OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-UHFFFAOYSA-N 0.000 claims description 7
- 235000019152 folic acid Nutrition 0.000 claims description 7
- 239000011724 folic acid Substances 0.000 claims description 7
- 229960000304 folic acid Drugs 0.000 claims description 7
- 235000008164 pyridoxal Nutrition 0.000 claims description 7
- 239000011674 pyridoxal Substances 0.000 claims description 7
- 229960003581 pyridoxal Drugs 0.000 claims description 7
- 235000019231 riboflavin-5'-phosphate Nutrition 0.000 claims description 7
- 239000012453 solvate Substances 0.000 claims description 7
- QYXKQNMJTHPKBP-UHFFFAOYSA-N 1-(4-hydroxy-3-methoxyphenyl)decane-3,5-diol Chemical compound CCCCCC(O)CC(O)CCC1=CC=C(O)C(OC)=C1 QYXKQNMJTHPKBP-UHFFFAOYSA-N 0.000 claims description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 6
- 229960003790 alimemazine Drugs 0.000 claims description 6
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 claims description 6
- 229960000930 hydroxyzine Drugs 0.000 claims description 6
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims description 6
- 229960000582 mepyramine Drugs 0.000 claims description 6
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims description 5
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 5
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 5
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 claims description 5
- LGZSMXJRMTYABD-MDZDMXLPSA-N [8]-Shogaol Chemical compound CCCCCCC\C=C\C(=O)CCC1=CC=C(O)C(OC)=C1 LGZSMXJRMTYABD-MDZDMXLPSA-N 0.000 claims description 5
- 229940035676 analgesics Drugs 0.000 claims description 5
- 239000000730 antalgic agent Substances 0.000 claims description 5
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 5
- 229940110767 coenzyme Q10 Drugs 0.000 claims description 5
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 5
- 235000008191 folinic acid Nutrition 0.000 claims description 5
- 239000011672 folinic acid Substances 0.000 claims description 5
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims description 5
- 229960001691 leucovorin Drugs 0.000 claims description 5
- ZNOVTXRBGFNYRX-ABLWVSNPSA-N levomefolic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-ABLWVSNPSA-N 0.000 claims description 5
- 235000007635 levomefolic acid Nutrition 0.000 claims description 5
- 239000011578 levomefolic acid Substances 0.000 claims description 5
- WFNAKBGANONZEQ-UHFFFAOYSA-N 1-[(4-chlorophenyl)-phenylmethyl]-4-methylpiperazine Chemical compound C1CN(C)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 WFNAKBGANONZEQ-UHFFFAOYSA-N 0.000 claims description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 4
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 4
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 claims description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 4
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 4
- UFLGIAIHIAPJJC-UHFFFAOYSA-N Tripelennamine Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CC=C1 UFLGIAIHIAPJJC-UHFFFAOYSA-N 0.000 claims description 4
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 4
- 229930003779 Vitamin B12 Natural products 0.000 claims description 4
- 229930003268 Vitamin C Natural products 0.000 claims description 4
- FADFGCOCHHNRHF-VAWYXSNFSA-N [10]-Shogaol Chemical compound CCCCCCCCC\C=C\C(=O)CCC1=CC=C(O)C(OC)=C1 FADFGCOCHHNRHF-VAWYXSNFSA-N 0.000 claims description 4
- TYQRTQZWHUXDLG-UHFFFAOYSA-N [8]-Paradol Chemical compound CCCCCCCCCC(=O)CCC1=CC=C(O)C(OC)=C1 TYQRTQZWHUXDLG-UHFFFAOYSA-N 0.000 claims description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 4
- ZDIGNSYAACHWNL-UHFFFAOYSA-N brompheniramine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Br)C=C1 ZDIGNSYAACHWNL-UHFFFAOYSA-N 0.000 claims description 4
- 229960000725 brompheniramine Drugs 0.000 claims description 4
- 229960001948 caffeine Drugs 0.000 claims description 4
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 4
- 229960004831 chlorcyclizine Drugs 0.000 claims description 4
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims description 4
- 229960001474 meclozine Drugs 0.000 claims description 4
- 229960003512 nicotinic acid Drugs 0.000 claims description 4
- 229960005489 paracetamol Drugs 0.000 claims description 4
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 claims description 4
- 229910052711 selenium Inorganic materials 0.000 claims description 4
- 239000011669 selenium Substances 0.000 claims description 4
- 229960003223 tripelennamine Drugs 0.000 claims description 4
- 229940040064 ubiquinol Drugs 0.000 claims description 4
- QNTNKSLOFHEFPK-UPTCCGCDSA-N ubiquinol-10 Chemical compound COC1=C(O)C(C)=C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=C1OC QNTNKSLOFHEFPK-UPTCCGCDSA-N 0.000 claims description 4
- 235000019155 vitamin A Nutrition 0.000 claims description 4
- 239000011719 vitamin A Substances 0.000 claims description 4
- 235000019163 vitamin B12 Nutrition 0.000 claims description 4
- 239000011715 vitamin B12 Substances 0.000 claims description 4
- 235000019154 vitamin C Nutrition 0.000 claims description 4
- 239000011718 vitamin C Substances 0.000 claims description 4
- 229940045997 vitamin a Drugs 0.000 claims description 4
- 239000011701 zinc Substances 0.000 claims description 4
- 229910052725 zinc Inorganic materials 0.000 claims description 4
- 108010024636 Glutathione Proteins 0.000 claims description 3
- 108010068370 Glutens Proteins 0.000 claims description 3
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 3
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- IJHNSHDBIRRJRN-UHFFFAOYSA-N N,N-dimethyl-3-phenyl-3-(2-pyridinyl)-1-propanamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=CC=C1 IJHNSHDBIRRJRN-UHFFFAOYSA-N 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 3
- ISFHAYSTHMVOJR-UHFFFAOYSA-N Phenindamine Chemical compound C1N(C)CCC(C2=CC=CC=C22)=C1C2C1=CC=CC=C1 ISFHAYSTHMVOJR-UHFFFAOYSA-N 0.000 claims description 3
- 229930003537 Vitamin B3 Natural products 0.000 claims description 3
- JLXKTAQNHHXFHL-MFDVASPDSA-N [6]-Dehydroshogaol Chemical compound CCCCC\C=C\C(=O)\C=C\C1=CC=C(O)C(OC)=C1 JLXKTAQNHHXFHL-MFDVASPDSA-N 0.000 claims description 3
- KMNVXQHNIWUUSE-UHFFFAOYSA-N [6]-Gingerdione Chemical compound CCCCCC(=O)CC(=O)CCC1=CC=C(O)C(OC)=C1 KMNVXQHNIWUUSE-UHFFFAOYSA-N 0.000 claims description 3
- 229940064063 alpha tocotrienol Drugs 0.000 claims description 3
- RZFHLOLGZPDCHJ-DLQZEEBKSA-N alpha-Tocotrienol Natural products Oc1c(C)c(C)c2O[C@@](CC/C=C(/CC/C=C(\CC/C=C(\C)/C)/C)\C)(C)CCc2c1C RZFHLOLGZPDCHJ-DLQZEEBKSA-N 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 3
- 239000005557 antagonist Substances 0.000 claims description 3
- REYFJDPCWQRWAA-UHFFFAOYSA-N antazoline Chemical compound N=1CCNC=1CN(C=1C=CC=CC=1)CC1=CC=CC=C1 REYFJDPCWQRWAA-UHFFFAOYSA-N 0.000 claims description 3
- 229960002469 antazoline Drugs 0.000 claims description 3
- SEBMTIQKRHYNIT-UHFFFAOYSA-N azatadine Chemical compound C1CN(C)CCC1=C1C2=NC=CC=C2CCC2=CC=CC=C21 SEBMTIQKRHYNIT-UHFFFAOYSA-N 0.000 claims description 3
- 229960000383 azatadine Drugs 0.000 claims description 3
- 229960003166 bromazine Drugs 0.000 claims description 3
- ZQDJSWUEGOYDGT-UHFFFAOYSA-N bromazine hydrochloride Chemical compound [Cl-].C=1C=C(Br)C=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 ZQDJSWUEGOYDGT-UHFFFAOYSA-N 0.000 claims description 3
- 239000001506 calcium phosphate Substances 0.000 claims description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 3
- 235000011010 calcium phosphates Nutrition 0.000 claims description 3
- OJFSXZCBGQGRNV-UHFFFAOYSA-N carbinoxamine Chemical compound C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 OJFSXZCBGQGRNV-UHFFFAOYSA-N 0.000 claims description 3
- 229960000428 carbinoxamine Drugs 0.000 claims description 3
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 claims description 3
- 229960003291 chlorphenamine Drugs 0.000 claims description 3
- 229960002881 clemastine Drugs 0.000 claims description 3
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 claims description 3
- 238000013329 compounding Methods 0.000 claims description 3
- 235000013365 dairy product Nutrition 0.000 claims description 3
- ZDIGNSYAACHWNL-HNNXBMFYSA-N dexbrompheniramine Chemical compound C1([C@H](CCN(C)C)C=2N=CC=CC=2)=CC=C(Br)C=C1 ZDIGNSYAACHWNL-HNNXBMFYSA-N 0.000 claims description 3
- 229960002691 dexbrompheniramine Drugs 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 229940013640 flavin mononucleotide Drugs 0.000 claims description 3
- 235000021312 gluten Nutrition 0.000 claims description 3
- 229910052742 iron Inorganic materials 0.000 claims description 3
- 229960004958 ketotifen Drugs 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 235000019136 lipoic acid Nutrition 0.000 claims description 3
- 239000011777 magnesium Substances 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 229960005336 magnesium citrate Drugs 0.000 claims description 3
- 239000004337 magnesium citrate Substances 0.000 claims description 3
- 235000002538 magnesium citrate Nutrition 0.000 claims description 3
- 229940004916 magnesium glycinate Drugs 0.000 claims description 3
- 229940091250 magnesium supplement Drugs 0.000 claims description 3
- AACACXATQSKRQG-UHFFFAOYSA-L magnesium;2-aminoacetate Chemical compound [Mg+2].NCC([O-])=O.NCC([O-])=O AACACXATQSKRQG-UHFFFAOYSA-L 0.000 claims description 3
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 3
- QVYRGXJJSLMXQH-UHFFFAOYSA-N orphenadrine Chemical compound C=1C=CC=C(C)C=1C(OCCN(C)C)C1=CC=CC=C1 QVYRGXJJSLMXQH-UHFFFAOYSA-N 0.000 claims description 3
- 229960003941 orphenadrine Drugs 0.000 claims description 3
- 229960003534 phenindamine Drugs 0.000 claims description 3
- 229960001190 pheniramine Drugs 0.000 claims description 3
- IZRPKIZLIFYYKR-UHFFFAOYSA-N phenyltoloxamine Chemical compound CN(C)CCOC1=CC=CC=C1CC1=CC=CC=C1 IZRPKIZLIFYYKR-UHFFFAOYSA-N 0.000 claims description 3
- 229960001526 phenyltoloxamine Drugs 0.000 claims description 3
- 239000010452 phosphate Substances 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
- 239000006041 probiotic Substances 0.000 claims description 3
- 235000018291 probiotics Nutrition 0.000 claims description 3
- 229960000342 retinol acetate Drugs 0.000 claims description 3
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 claims description 3
- 235000019173 retinyl acetate Nutrition 0.000 claims description 3
- 239000011770 retinyl acetate Substances 0.000 claims description 3
- 150000003287 riboflavins Chemical class 0.000 claims description 3
- 229940091258 selenium supplement Drugs 0.000 claims description 3
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 claims description 3
- 229960002663 thioctic acid Drugs 0.000 claims description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 3
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 claims description 3
- 235000019160 vitamin B3 Nutrition 0.000 claims description 3
- 239000011708 vitamin B3 Substances 0.000 claims description 3
- RZFHLOLGZPDCHJ-XZXLULOTSA-N α-Tocotrienol Chemical compound OC1=C(C)C(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1C RZFHLOLGZPDCHJ-XZXLULOTSA-N 0.000 claims description 3
- 235000019145 α-tocotrienol Nutrition 0.000 claims description 3
- 239000011730 α-tocotrienol Substances 0.000 claims description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 229940126409 proton pump inhibitor Drugs 0.000 claims description 2
- 239000000612 proton pump inhibitor Substances 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 abstract description 191
- 229940011671 vitamin b6 Drugs 0.000 abstract description 109
- 235000019158 vitamin B6 Nutrition 0.000 abstract description 71
- 239000011726 vitamin B6 Substances 0.000 abstract description 71
- 230000003474 anti-emetic effect Effects 0.000 abstract description 40
- 230000001062 anti-nausea Effects 0.000 abstract description 20
- 230000000144 pharmacologic effect Effects 0.000 abstract description 13
- 230000009471 action Effects 0.000 abstract description 7
- 230000008289 pathophysiological mechanism Effects 0.000 abstract description 5
- 244000273928 Zingiber officinale Species 0.000 description 122
- 229940079593 drug Drugs 0.000 description 36
- 239000000470 constituent Substances 0.000 description 29
- 238000007726 management method Methods 0.000 description 25
- 238000009472 formulation Methods 0.000 description 24
- 239000000047 product Substances 0.000 description 22
- 229940125715 antihistaminic agent Drugs 0.000 description 21
- 239000002111 antiemetic agent Substances 0.000 description 20
- 239000003826 tablet Substances 0.000 description 20
- 102000005962 receptors Human genes 0.000 description 19
- 108020003175 receptors Proteins 0.000 description 19
- 201000003152 motion sickness Diseases 0.000 description 18
- 230000035935 pregnancy Effects 0.000 description 18
- 210000001035 gastrointestinal tract Anatomy 0.000 description 15
- 239000004480 active ingredient Substances 0.000 description 14
- 239000002552 dosage form Substances 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 13
- 235000008160 pyridoxine Nutrition 0.000 description 13
- 239000011677 pyridoxine Substances 0.000 description 13
- 208000005577 Gastroenteritis Diseases 0.000 description 12
- 238000011394 anticancer treatment Methods 0.000 description 12
- 210000003169 central nervous system Anatomy 0.000 description 12
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 12
- 238000001356 surgical procedure Methods 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- 238000004806 packaging method and process Methods 0.000 description 11
- 239000000306 component Substances 0.000 description 10
- 230000036541 health Effects 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 8
- 230000008499 blood brain barrier function Effects 0.000 description 8
- 210000001218 blood-brain barrier Anatomy 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 230000036542 oxidative stress Effects 0.000 description 8
- 208000009233 Morning Sickness Diseases 0.000 description 7
- 208000034850 Vomiting in pregnancy Diseases 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 238000002512 chemotherapy Methods 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 229960001327 pyridoxal phosphate Drugs 0.000 description 6
- KBAUFVUYFNWQFM-UHFFFAOYSA-N Doxylamine succinate Chemical compound OC(=O)CCC(O)=O.C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 KBAUFVUYFNWQFM-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 5
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 5
- 208000031649 Postoperative Nausea and Vomiting Diseases 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 229960005008 doxylamine succinate Drugs 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 5
- 229960004503 metoclopramide Drugs 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 229940044551 receptor antagonist Drugs 0.000 description 5
- 239000002464 receptor antagonist Substances 0.000 description 5
- 229940076279 serotonin Drugs 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- RSAHICAPUYTWHW-UHFFFAOYSA-N Hexahydrocurcumin Chemical compound C1=C(O)C(OC)=CC(CCC(O)CC(=O)CCC=2C=C(OC)C(O)=CC=2)=C1 RSAHICAPUYTWHW-UHFFFAOYSA-N 0.000 description 4
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 229940125683 antiemetic agent Drugs 0.000 description 4
- 210000003818 area postrema Anatomy 0.000 description 4
- 125000003636 chemical group Chemical group 0.000 description 4
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 238000002483 medication Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- 229940005483 opioid analgesics Drugs 0.000 description 4
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 3
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 3
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 3
- 101000831616 Homo sapiens Protachykinin-1 Proteins 0.000 description 3
- 102000005954 Methylenetetrahydrofolate Reductase (NADPH2) Human genes 0.000 description 3
- 108010030837 Methylenetetrahydrofolate Reductase (NADPH2) Proteins 0.000 description 3
- 102100024304 Protachykinin-1 Human genes 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 208000003056 Vitamin B6 deficiency Diseases 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000006172 buffering agent Substances 0.000 description 3
- 108091008690 chemoreceptors Proteins 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 239000013065 commercial product Substances 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 210000003027 ear inner Anatomy 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000003551 muscarinic effect Effects 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 229960005343 ondansetron Drugs 0.000 description 3
- 239000006191 orally-disintegrating tablet Substances 0.000 description 3
- 230000007310 pathophysiology Effects 0.000 description 3
- 229960003111 prochlorperazine Drugs 0.000 description 3
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- LACQPOBCQQPVIT-SEYKEWMNSA-N scopolamine hydrobromide trihydrate Chemical compound O.O.O.Br.C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 LACQPOBCQQPVIT-SEYKEWMNSA-N 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- ADNPLDHMAVUMIW-CUZNLEPHSA-N substance P Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 238000012384 transportation and delivery Methods 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- CXENHBSYCFFKJS-VDQVFBMKSA-N (E,E)-alpha-farnesene Chemical compound CC(C)=CCC\C(C)=C\C\C=C(/C)C=C CXENHBSYCFFKJS-VDQVFBMKSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 206010003011 Appendicitis Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010006550 Bulimia nervosa Diseases 0.000 description 2
- 208000025721 COVID-19 Diseases 0.000 description 2
- DBAKFASWICGISY-DASCVMRKSA-N Dexchlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C1([C@H](CCN(C)C)C=2N=CC=CC=2)=CC=C(Cl)C=C1 DBAKFASWICGISY-DASCVMRKSA-N 0.000 description 2
- 229940121891 Dopamine receptor antagonist Drugs 0.000 description 2
- 206010016952 Food poisoning Diseases 0.000 description 2
- 208000019331 Foodborne disease Diseases 0.000 description 2
- 206010017918 Gastroenteritis viral Diseases 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- FWDXZNKYDTXGOT-GQCTYLIASA-N Gingerenone A Chemical compound C1=C(O)C(OC)=CC(CC\C=C\C(=O)CCC=2C=C(OC)C(O)=CC=2)=C1 FWDXZNKYDTXGOT-GQCTYLIASA-N 0.000 description 2
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 2
- 206010020850 Hyperthyroidism Diseases 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 206010021518 Impaired gastric emptying Diseases 0.000 description 2
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 2
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 206010041660 Splenomegaly Diseases 0.000 description 2
- 102100037346 Substance-P receptor Human genes 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 229940124326 anaesthetic agent Drugs 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000001078 anti-cholinergic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000561 anti-psychotic effect Effects 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 239000000164 antipsychotic agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229940046011 buccal tablet Drugs 0.000 description 2
- 239000006189 buccal tablet Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000007910 chewable tablet Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 2
- 210000000959 ear middle Anatomy 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000002662 enteric coated tablet Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 2
- 229960001596 famotidine Drugs 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 208000001288 gastroparesis Diseases 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 239000000938 histamine H1 antagonist Substances 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 208000003243 intestinal obstruction Diseases 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 230000003232 mucoadhesive effect Effects 0.000 description 2
- WAXQNWCZJDTGBU-UHFFFAOYSA-N netupitant Chemical compound C=1N=C(N2CCN(C)CC2)C=C(C=2C(=CC=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 WAXQNWCZJDTGBU-UHFFFAOYSA-N 0.000 description 2
- 229960005163 netupitant Drugs 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000000820 nonprescription drug Substances 0.000 description 2
- 229940078646 other antiemetics in atc Drugs 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 229960002131 palonosetron Drugs 0.000 description 2
- CPZBLNMUGSZIPR-NVXWUHKLSA-N palonosetron Chemical compound C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1 CPZBLNMUGSZIPR-NVXWUHKLSA-N 0.000 description 2
- 230000000849 parathyroid Effects 0.000 description 2
- 229940107333 phenergan Drugs 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- KKOXKGNSUHTUBV-UHFFFAOYSA-N racemic zingiberene Natural products CC(C)=CCCC(C)C1CC=C(C)C=C1 KKOXKGNSUHTUBV-UHFFFAOYSA-N 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229960002646 scopolamine Drugs 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000006190 sub-lingual tablet Substances 0.000 description 2
- 229940098466 sublingual tablet Drugs 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- OJYLAHXKWMRDGS-UHFFFAOYSA-N zingerone Chemical compound COC1=CC(CCC(C)=O)=CC=C1O OJYLAHXKWMRDGS-UHFFFAOYSA-N 0.000 description 2
- KKOXKGNSUHTUBV-LSDHHAIUSA-N zingiberene Chemical compound CC(C)=CCC[C@H](C)[C@H]1CC=C(C)C=C1 KKOXKGNSUHTUBV-LSDHHAIUSA-N 0.000 description 2
- 229930001895 zingiberene Natural products 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- AIULWNKTYPZYAN-SFHVURJKSA-N (10)-Gingerol Chemical compound CCCCCCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 AIULWNKTYPZYAN-SFHVURJKSA-N 0.000 description 1
- FZWNRFAUDBWSKY-QNQPVOBRSA-N (1e,3z)-3-hydroxy-1-(4-hydroxy-3-methoxyphenyl)deca-1,3-dien-5-one Chemical compound CCCCCC(=O)\C=C(/O)\C=C\C1=CC=C(O)C(OC)=C1 FZWNRFAUDBWSKY-QNQPVOBRSA-N 0.000 description 1
- ZNOVTXRBGFNYRX-STQMWFEESA-N (6S)-5-methyltetrahydrofolic acid Chemical compound C([C@@H]1N(C=2C(=O)N=C(N)NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-STQMWFEESA-N 0.000 description 1
- JUKHKHMSQCQHEN-VQHVLOKHSA-N 1-Dehydro-[6]-gingerdione Natural products CCCCCC(=O)CC(=O)\C=C\C1=CC=C(O)C(OC)=C1 JUKHKHMSQCQHEN-VQHVLOKHSA-N 0.000 description 1
- YPFNIPKMNMDDDB-UHFFFAOYSA-K 2-[2-[bis(carboxylatomethyl)amino]ethyl-(2-hydroxyethyl)amino]acetate;iron(3+) Chemical compound [Fe+3].OCCN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O YPFNIPKMNMDDDB-UHFFFAOYSA-K 0.000 description 1
- XXQVGYBHEUJCNV-UHFFFAOYSA-N 2-methoxy-4-[2-(5-propylfuran-2-yl)ethyl]phenol Chemical compound O1C(CCC)=CC=C1CCC1=CC=C(O)C(OC)=C1 XXQVGYBHEUJCNV-UHFFFAOYSA-N 0.000 description 1
- SKNCYEAIKRVFGR-UHFFFAOYSA-N 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol;butanedioic acid;2-(diethylamino)ethyl 1-cyclohexylcyclohexane-1-carboxylate;n,n-dimethyl-2-(1-phenyl-1-pyridin-2-ylethoxy)ethanamine;dihydrochloride Chemical compound Cl.Cl.OC(=O)CCC(O)=O.CC1=NC=C(CO)C(CO)=C1O.C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1.C1CCCCC1C1(C(=O)OCCN(CC)CC)CCCCC1 SKNCYEAIKRVFGR-UHFFFAOYSA-N 0.000 description 1
- AAYNMUXDBOPKCP-UHFFFAOYSA-N 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol;butanedioic acid;n,n-dimethyl-2-(1-phenyl-1-pyridin-2-ylethoxy)ethanamine;hydron;chloride Chemical compound Cl.OC(=O)CCC(O)=O.CC1=NC=C(CO)C(CO)=C1O.C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 AAYNMUXDBOPKCP-UHFFFAOYSA-N 0.000 description 1
- 108091005477 5-HT3 receptors Proteins 0.000 description 1
- 102000035037 5-HT3 receptors Human genes 0.000 description 1
- ZEASWHWETFMWCV-UHFFFAOYSA-N 7-O-(2-O-Acetyl-6-O-Methyl-beta-D-glucuronoside)-4',5,7-Trihydroxyflavone Natural products C=1C(O)=C(O)C2=C(O)C(=O)C=C(C3C(CC4=C(O)C=C(O)C=C4O3)OC(=O)C=3C=C(O)C(O)=C(O)C=3)C=C2C=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 ZEASWHWETFMWCV-UHFFFAOYSA-N 0.000 description 1
- VSDUZFOSJDMAFZ-UHFFFAOYSA-N 8-gingerol Natural products COC(=O)C(N)CC1=CC=CC=C1 VSDUZFOSJDMAFZ-UHFFFAOYSA-N 0.000 description 1
- AIULWNKTYPZYAN-UHFFFAOYSA-N 810gingerol Natural products CCCCCCCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 AIULWNKTYPZYAN-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 208000007788 Acute Liver Failure Diseases 0.000 description 1
- 206010000804 Acute hepatic failure Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000034577 Benign intracranial hypertension Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- MREOWKKCLXWFQY-UHFFFAOYSA-N Cc1ncc(CO)c(C=O)c1O.Cc1ncc(COP(O)(O)=O)c(C=O)c1O Chemical compound Cc1ncc(CO)c(C=O)c1O.Cc1ncc(COP(O)(O)=O)c(C=O)c1O MREOWKKCLXWFQY-UHFFFAOYSA-N 0.000 description 1
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010010254 Concussion Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- VMYXUZSZMNBRCN-AWEZNQCLSA-N Curcumene Natural products CC(C)=CCC[C@H](C)C1=CC=C(C)C=C1 VMYXUZSZMNBRCN-AWEZNQCLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 206010011953 Decreased activity Diseases 0.000 description 1
- VBKDALTZEUBYTQ-RBMCBPMHSA-N Dehydrogingerdione Natural products COc1cc(\C=C\C(\O)=C/C(C)=O)ccc1O VBKDALTZEUBYTQ-RBMCBPMHSA-N 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 208000001380 Diabetic Ketoacidosis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 240000001879 Digitalis lutea Species 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 206010016825 Flushing Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- 108010063907 Glutathione Reductase Proteins 0.000 description 1
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 1
- FWKQNCXZGNBPFD-UHFFFAOYSA-N Guaiazulene Chemical compound CC(C)C1=CC=C(C)C2=CC=C(C)C2=C1 FWKQNCXZGNBPFD-UHFFFAOYSA-N 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019670 Hepatic function abnormal Diseases 0.000 description 1
- 208000034991 Hiatal Hernia Diseases 0.000 description 1
- 206010020028 Hiatus hernia Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000005420 Hyperemesis Gravidarum Diseases 0.000 description 1
- 201000002980 Hyperparathyroidism Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000000038 Hypoparathyroidism Diseases 0.000 description 1
- 208000018127 Idiopathic intracranial hypertension Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010022680 Intestinal ischaemia Diseases 0.000 description 1
- 206010059491 Intracranial haematoma Diseases 0.000 description 1
- 206010022773 Intracranial pressure increased Diseases 0.000 description 1
- 208000005168 Intussusception Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 206010023567 Labyrinthitis Diseases 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 235000004049 Mentha X gracilis Nutrition 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CTGAPJBPSCUFRO-UHFFFAOYSA-N Methylgingerol Natural products CCCCCC(O)CC(=O)CCC1=CC=C(OC)C(OC)=C1 CTGAPJBPSCUFRO-UHFFFAOYSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000009793 Milk Hypersensitivity Diseases 0.000 description 1
- 201000010859 Milk allergy Diseases 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 201000000660 Pyloric Stenosis Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 244000235659 Rubus idaeus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- 208000037175 Travel-Related Illness Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010047348 Vertigo positional Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- 240000008866 Ziziphus nummularia Species 0.000 description 1
- JSZILQVIPPROJI-CEXWTWQISA-N [(2R,3R,11bS)-3-(diethylcarbamoyl)-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl] acetate Chemical compound C1CC2=CC(OC)=C(OC)C=C2[C@H]2N1C[C@@H](C(=O)N(CC)CC)[C@H](OC(C)=O)C2 JSZILQVIPPROJI-CEXWTWQISA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 231100000836 acute liver failure Toxicity 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 229940029184 akynzeo Drugs 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001705 anti-serotonergic effect Effects 0.000 description 1
- 239000003911 antiadherent Substances 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229940124537 antidiarrhoeal agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 239000003420 antiserotonin agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960001372 aprepitant Drugs 0.000 description 1
- ATALOFNDEOCMKK-OITMNORJSA-N aprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNC(=O)N1 ATALOFNDEOCMKK-OITMNORJSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000002199 base oil Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 201000000691 benign paroxysmal positional nystagmus Diseases 0.000 description 1
- 208000001870 benign paroxysmal positional vertigo Diseases 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 229960004564 benzquinamide Drugs 0.000 description 1
- PHWISBHSBNDZDX-UHFFFAOYSA-N beta-Sesquiphellandrene Natural products CC(C)=CCCC(C)C1CCC(=C)C=C1 PHWISBHSBNDZDX-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- ZREIPSZUJIFJNP-UHFFFAOYSA-K bismuth subsalicylate Chemical compound C1=CC=C2O[Bi](O)OC(=O)C2=C1 ZREIPSZUJIFJNP-UHFFFAOYSA-K 0.000 description 1
- 229960000782 bismuth subsalicylate Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- MOYGZHXDRJNJEP-UHFFFAOYSA-N buclizine Chemical compound C1=CC(C(C)(C)C)=CC=C1CN1CCN(C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1 MOYGZHXDRJNJEP-UHFFFAOYSA-N 0.000 description 1
- 229960001705 buclizine Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 229940065144 cannabinoids Drugs 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 239000008358 core component Substances 0.000 description 1
- 239000011162 core material Substances 0.000 description 1
- 206010062937 cyclic vomiting syndrome Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- VWHYFMQKJYFLCC-UHFFFAOYSA-N dehydrohirsutanonol Natural products C1=C(O)C(O)=CC=C1CCC=CC(=O)CCC1=CC=C(O)C(O)=C1 VWHYFMQKJYFLCC-UHFFFAOYSA-N 0.000 description 1
- 239000007950 delayed release tablet Substances 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940067199 doxylamine succinate 25 mg Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000002355 dual-layer Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000002895 emetic Substances 0.000 description 1
- 230000000095 emetic effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 210000004055 fourth ventricle Anatomy 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940102465 ginger root Drugs 0.000 description 1
- 229930184876 gingerenone Natural products 0.000 description 1
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 1
- 229960003727 granisetron Drugs 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 235000015810 grayleaf red raspberry Nutrition 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- 229940124512 hyoscine hydrobromide Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229960003208 levomefolic acid Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 235000011475 lollipops Nutrition 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000968 medical method and process Methods 0.000 description 1
- 210000001767 medulla oblongata Anatomy 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000003818 metabolic dysfunction Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
- 229960001869 methapyrilene Drugs 0.000 description 1
- HNJJXZKZRAWDPF-UHFFFAOYSA-N methapyrilene Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CS1 HNJJXZKZRAWDPF-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000002742 neurokinin 1 receptor antagonist Substances 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- SGXXNSQHWDMGGP-IZZDOVSWSA-N nizatidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CSC(CN(C)C)=N1 SGXXNSQHWDMGGP-IZZDOVSWSA-N 0.000 description 1
- 229960004872 nizatidine Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940054010 other antipsychotics in atc Drugs 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 229940124583 pain medication Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 150000002990 phenothiazines Chemical class 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 208000001381 pseudotumor cerebri Diseases 0.000 description 1
- 235000019170 pyridoxine-5-phosphate Nutrition 0.000 description 1
- 239000011763 pyridoxine-5-phosphate Substances 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 229930002224 sesquiphellandrene Natural products 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000008137 solubility enhancer Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 229940105022 spearmint extract Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- 231100000378 teratogenic Toxicity 0.000 description 1
- 230000003390 teratogenic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- FEZBIKUBAYAZIU-UHFFFAOYSA-N trimethobenzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NCC=2C=CC(OCCN(C)C)=CC=2)=C1 FEZBIKUBAYAZIU-UHFFFAOYSA-N 0.000 description 1
- 229960004161 trimethobenzamide Drugs 0.000 description 1
- 229960003688 tropisetron Drugs 0.000 description 1
- UIVFDCIXTSJXBB-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C[C]2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CN=C21 UIVFDCIXTSJXBB-ITGUQSILSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000001720 vestibular Effects 0.000 description 1
- 201000000200 vestibular neuronitis Diseases 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 150000003697 vitamin B6 derivatives Chemical class 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 239000001841 zingiber officinale Substances 0.000 description 1
- 239000001243 zingiber officinale rosc. root absolute Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- the present invention relates to compositions, kits and methods for the prevention, treatment and management of nausea and vomiting with a known or unknown underlying cause, including but not limited to pregnancy, motion sickness, drug use, alcohol use, gastroenteritis, polycystic ovary syndrome, anti-cancer treatment and surgery.
- nausea refers to a sense of an urge to vomit, while ‘vomit’ is the oral expulsion of the gastrointestinal content.
- Nausea and vomiting could be acute or chronic.
- Nausea and vomiting are symptoms of an underlying condition such as pregnancy, motion sickness, drug use, alcohol use, gastroenteritis, polycystic ovary syndrome (PCOS), anti-cancer treatment and surgery.
- Nausea and vomiting are an outcome of stimulation of receptors in the CNS and gut through various mechanisms.
- NVP Nausea and vomiting in pregnancy referred herein as NVP could be frequent or infrequent and may even last throughout the pregnancy in some women. It could be mild or severe to the extent that it may require frequent pharmacological and/or non-pharmacological interventions. Severe NVP is known as hyperemesis gravidarum and may require treatment in the hospital. Pathophysiology of NVP are hormones, neurotransmitters and receptors mediated.
- Drugs can trigger nausea, and/or vomiting in some patients, and it is subjective. Besides anticancer drugs, some other drugs may induce NV in some patients. Commonly known drugs that cause NV include anti-depressants, opioids, anti-inflammatories, contraceptives, hormone replacement therapy (HRT) drugs and anti-psychotics. Drug-induced NV generally occurs when new drug treatment is initiated and often goes away after several days of continuation of the drug. In some conditions, medication is necessary to prevent, treat and manage NV associated with a drug. Withdrawal of some medication can also cause NV. [05] Alcohol in excess amount is a toxin for the body. Alcohol breaks down into acetaldehyde in liver and this process produces harmful chemical which causes inflammation in the gastrointestinal tract and could result into nausea or vomiting. Untreated vomiting can cause dehydration.
- Motion sickness is the feeling of being sick because of a motion. Receptors in the CNS and gut are activated when the body struggles to adjust with the motion; the brain receives conflicting information from the inner ears, eyes and nerves. Common symptoms of motion sickness are nausea with or without vomiting. Travel sickness, seasickness, airsickness, train sickness are types of motion sickness. It can also be caused by swinging, bumping, rotation, deceleration movement and various reasons.
- Gastroenteritis is the gut inflammation caused by the virus, bacteria, fungi, parasites, toxins or drugs, sometimes referred as ‘stomach bug’, stomach flu or food poisoning. Besides nausea and vomiting, diarrhoea, stomach cramps, fever, and headaches are also symptoms of gastroenteritis.
- homocysteine In Polycystic ovary syndrome (PCOS), levels of an amino acid named homocysteine remain high. High levels of homocysteine increase inflammation, oxidative stress and increase the risk of atherosclerosis and thrombosis. In addition, high homocysteine level causes nausea, vomiting and fatigue. Vitamin B6 plays an essential role in the breakdown of homocysteine.
- PCOS Polycystic ovary syndrome
- CINV Chemotherapy-induced nausea and vomiting
- AINV anti-cancer treatment induced nausea and vomiting
- PONV Post-Operative Nausea and Vomiting
- US patent no. 20070048367 relates to a herbal composition for treating morning sickness and includes a mixture of vitamin B6, folic acid, ginger root extract, and red raspberry leaf.
- US patent no. US20170049759 & EP patent no. EP3337480 relates to transdermal delivery of doxylamine and pyridoxine.
- the formulation includes doxylamine or its salts, pyridoxine or its salts or its active metabolites, and a vehicle system wherein pharmaceutical compositions are liquid formulations, semisolid formulations, and polymer matrices for treatment of nausea and vomiting in general and pregnant women in particular.
- WO patent no 2000066082 & AU patent no. 2000049779 relates to anti-nausea compositions and methods. It discloses novel nutritional anti-nausea compositions, anti-emetic compositions, and methods of using the same.
- the compositions comprise a vitamin B6 compound or derivative thereof; an alkaline buffering agent, an acceptable coating agent; and wherein the vitamin B6 compound or derivative thereof is separated from the alkaline buffering agent by the said acceptable coating agent.
- US patent no. 6340695 relates to a rapid onset formulation, preferably in the form of an enteric- coated tablet, for a medicament comprising a synergistic duo of active ingredients, namely, doxylamine succinate and pyridoxine HC1, for the treatment of nausea and vomiting, especially, but not limited to, during pregnancy.
- active ingredients namely, doxylamine succinate and pyridoxine HC1
- US patent no. 20140314680 relates to a dual release oral dosage system/dosage form comprising an immediate release component/composition and a delayed-release component/composition comprising one or more of doxylamine, an analog thereof, a derivative thereof, a prodrug thereof, a metabolite thereof and/or a salt thereof, and one or more of pyridoxine, a salt thereof, a metabolite thereof and/or a salt of the metabolite for the prevention and/or treatment of nausea and vomiting in pregnancy (NVP).
- NDP nausea and vomiting in pregnancy
- US patent no. 20140335176 relates to a delayed release formulation containing doxylamine succinate and pyridoxine hydrochloride as the active ingredients in a disintegrant-free formulation and processes for manufacturing the same.
- US patent no. 20160058709 relates to plurimodal release formulation of metabolites and salts of doxylamine and pyridoxine.
- the patent covers the formulation with these active ingredients as component of enteric coating within the enteric-coated formulation comprising these active ingredients.
- Indian patent no. 202021002251 relates to a solid oral composition of doxylamine succinate, pyridoxine hydrochloride in combination with ginger powder as a natural extract as synergistic additive. It provides the solid oral composition in the form of granules/powder filled into sachets or compressed into tablets, especially chewable tablets for the treatment of nausea and vomiting.
- US patent no. 20110280976 relates to methods for making and using gingerols for treating nausea and emesis associated with cancer chemotherapy.
- the methods feature supercritical, critical and near-critical fluids with and without polar cosolvents.
- US patent no. 20110028436 relates to oral combination of vitamins for treating and preventing nausea and other disorders.
- the compositions comprise vitamins as active ingredients, including vitamin B6 and its metabolites, vitamin K, and vitamin C, and a method for treating nausea or morning sickness with the oral compositions.
- US patent no. 20130171279 relates to composition for reducing side- and after-effects of cancer treatment. It includes three core components: whey protein, hepatoprotectant and/or nephroprotectant agents and, anti-emetic agent(s) such as ginger and/or peppermint.
- US patent no. 20100291057 relates to a composition for reducing oxidative stress and/or side effects occurring during cancer chemotherapy or improving a nutritional status during cancer chemotherapy.
- the composition comprises the following components (a) to (f): (a) an antioxidant agent; (b) at least one component selected from the group consisting of vitamin Bl, vitamin B2, vitamin B6, niacin, and pantothenic acid; (c) at least one component selected from the group consisting of folic acid, vitamin B12, and vitamin A; (d) zinc; (e) selenium; and (f) coenzyme Q10.
- WO patent no. 1986002553 is a nasal administration of known anti-nausea and anti-emetic therapeutic agents and dosage forms which discloses the use of selected antihistamines, anticholinergics, piperazines, phenothiazines, substituted butyprophenes and metoclopramide.
- US patent no. 4624965 relates to novel method of administering anti-nausea and anti-emetic agents and to novel dosage forms which includes the use of brompheniramine, promethazine, cyproheptadine, dimenhydrinate, meclizine, cyclizine, chlorcyclizine, buclizine, trimethobenzamide, benzquinamide metoclopramide, diphenhydramine, doxylamine, methapyrilene and tripelennamine for nasal administration.
- US patent no. 20200113856 relates to a compounded non-prescription medication for the treatment of motion sickness.
- the medication comprises: at least one analgesic selected from the group consisting of acetaminophen, ibuprofen, naproxen and salicylates; at least one histamine H2-receptor antagonist selected from the group consisting of nizatidine, famotidine, cimetidine, ranitidine, famotidine; and at least one antacid selected from the group consisting of calcium carbonate, sodium bicarbonate, magnesium hydroxide, aluminum hydroxide, and bismuth subsalicylate. It may optionally comprise at least one additional ingredient selected from the group consisting of spearmint extract and ginger extract.
- US patent no. 08137709 relates to fast-acting nausea formula which comprise of ginger root, gelatin, a fruit flavouring, and mint.
- CN patent no. 106492159 relates anti-motion sickness drug which discloses the use of fresh ginger, fructusamomi, orange peel, chrysanthemum, and wild jujube.
- Sedative antihistamines such as doxylamine, promethazine, dexchlorpheniramine, cyclizine, diphenhydramine, dimenhydrinate is present in several products. Many formulations are available containing metoclopramide, prochlorperazine, ondansetron, and are used worldwide for NV.
- Vitamin B6 is included in treatment guidelines by several health authorities worldwide to prevent, treat, and manage NVP.
- a product called Elevit morning sickness tablets containing vitamin B6, and ginger is available without prescription in Australia and is being marketed for NVP.
- a fixed-dose combination of doxylamine succinate (20mg) and vitamin B6 (20mg pyridoxine hydrochloride) is being marketed under the brand name Bonjesta® in the USA for the management of NVP in women who have not improved with the change in diet or other non-medicine treatments.
- Diclectin® a combination of 10 mg doxylamine succinate and 10 mg vitamin B6 (pyridoxine hydrochloride) in a delayed-release tablet formulation, is available in Canada for women who have not benefited from the other therapies.
- Anti-emetics currently used for AINV include dopamine receptor antagonists such as metoclopramide, prochlorperazine, promethazine and haloperidol; serotonin (5HT3) receptor antagonists such as granisetron, ondansetron, palonosetron, tropisetron; neurokinin- 1 receptor antagonists (NK1 RA) such as aprepitant, netupitant.
- dopamine receptor antagonists such as metoclopramide, prochlorperazine, promethazine and haloperidol
- serotonin (5HT3) receptor antagonists such as granisetron, ondansetron, palonosetron, tropisetron
- NK1 RA neurokinin- 1 receptor antagonists
- Other anti-emetics used in AINV are dexamethasone (a steroid), olanzapine (for their inhibitory effects on 5HT3 and dopamine receptors) and cannabinoids (not commonly used).
- hyoscine hydrobromide Products containing scopolamine named hyoscine hydrobromide are currently available as a single ingredient under the brand name Kwells® and Travacalm HO®.
- Hyoscine combined with dimenhydrinate is available under the brand name Travacalm Original® to prevent and treat motion sickness.
- Doxylamine succinate 25 mg is available as ‘Pharmacist Only Medication’ for the temporary relief of insomnia or sleeplessness.
- the present invention is an improvement over the prior art in that it delivers the compositions, kits, and methods for the prevention, treatment, and management of NV via the pharmacological actions of the comprised ingredients into multiple pathophysiological mechanisms involved.
- Prior-art (Restavit , Phenergan , Polaramine ) products with only sedative antihistamine as anti-emetic ingredient increase sedation when administered at higher doses to achieve a higher antiemetic effect.
- the present invention provides compositions, kits, and methods that do not have the same disadvantage because these compositions achieve a higher anti-emetic effect with the lower dose of antihistamine via synergistic and/or additive effect of other comprised ingredients.
- the present invention also provides compositions, kits and methods that enable the use of sedative antihistamines when sleep is desirable.
- Prior art (Restavit®, Phenergan®, Polaramine®) products containing sedative antihistamine are ‘Pharmacist Only Medicine’. These products either do not have treatment of NV as an approved indication or has a warning statement on the packaging indicating possible harm if used during pregnancy 1 . Hence, the refusal by the pharmacist for the supply of these products for the treatment of NVP is common.
- Prior art product containing doxylamine provides this sedative antihistamine at a higher dose of 25mg only. Therefore, the patient requires to cut the tablet in half to obtain a lower dose.
- the present invention provides a lower dose of this antihistamine.
- compositions with both short and long- acting antihistamines are useful when sedation for 8 hrs or more is desired, whereas a composition comprising dexchlorpheniramine or other short-acting antihistamines is helpful when sedation for more than 6 hrs is to avoid.
- the present invention alleviates the need for caffeine which is included in a prior art (Travacalm original ) to counterbalance the sedative effect of sedative antihistamine.
- the present invention achieves this objective by not solely relying on sedative antihistamine to provide the antiemetic effect.
- the present invention provides compositions, kits, and methods comprising one or more (activated and/or one or more inactivated) forms of vitamin B6 and ginger (in standardised and/or non-standardised forms) to achieve the anti-emetic effect.
- NV is one of the symptoms of deficiency of vitamin B6.
- Vitamin B6 plays a vital role in the nervous system, metabolism pathways of NV. The body does not store vitamin B6, so people need to get from their daily diets 6 .
- Pyridoxal 5 ’-phosphate, pyridoxine 5’ phosphate, and pyridoxamine 5’ phosphate are activated forms of vitamin B6 ; and are also known as P5P or PLP, PNP, PMP, respectively.
- the conversion process from the inactive to the active form of vitamin B6 is enzyme- dependent ’ . Following the prevalence of relevant enzyme deficiencies, this conversion process does not occur the same way in all individuals.
- vitamin B6 Activated and inactivated forms of vitamin B6 levels are affected in patients with impaired liver functions 10 . Activated vitamin B6 levels are lower in a patient with Methylenetetrahydrofolate reductase (MTHFR) gene deficiency
- MTHFR Methylenetetrahydrofolate reductase
- An activated and inactivated form of vitamin B6 may be a more efficient therapy for morning sickness . Addressing underlying deficiency of vitamin B6 would result in better outcome compared to only managing the symptoms of NV using pyridoxine hydrochloride (an inactivated form of vitamin B6) and/or sedative antihistamine and/or 5H3 receptor antagonist comprised in other prior art products which do not contain an activated form of vitamin B6. Research suggests that the activated form of vitamin B6 is better anti-emetic than the inactive form of vitamin B6 for the management of NV 14 .
- the present invention provides compositions, kits, and method that addresses this underlying cause better than other prior art (Elevit Morning Sickness Relief®’Pyridox®) products.
- the chemical constituents of ginger vary significantly with species and geographical source 15 . Also, all constituents of ginger do not have identical biological and physiological properties 16 , 17 . Ginger is dried using different drying methods, and the chosen method impacts the constituents of the product at the end .
- the anti-emetic properties of ginger are mainly due to active constituents from groups called ‘gingerols’ and ‘shogaols’ 19 . Hence the therapeutic effect of all products containing ginger in non-standardised forms cannot be assumed the same.
- compositions comprising gingerols and shogaols in standardised forms, thereby provide unit doses with smaller volume, which would be hard to administer otherwise.
- the present invention provides scientifically identified anti-emetic ingredients of ginger in therapeutic doses. Compositions comprising such ingredients are more likely to be accepted and recommended by health care practitioners compared to ‘raw’ ginger present in prior art products.
- the present invention also provides compositions, kits, and methods without scheduled ingredients. These embodiments achieve anti-nausea and anti-emetic effects via constituents of ginger (in standardised and/or in non-standardised forms) and vitamin B6 (activated and/or inactivated forms) only.
- the present invention makes anti-emetic treatment options more accessible (without the intervention of a pharmacist or a doctor) to patients. Hence, it also reduces the health care cost of the government.
- NV involves multiple pathophysiological mechanisms.
- the present invention comprises multiple anti-emetic ingredients to provide additive and/or synergistic effects by acting on more than one pathophysiological mechanism.
- compositions comprising standardised ginger and sedative antihistamines that target receptors present in both the CNS and gut.
- compositions comprising one or more activated forms and/or one or more inactivated forms of vitamin B6 and/or ginger in standardised or in nonstandardised forms, which would suit better to such population.
- Uncomplicated NV does not always require attention from the doctor. Uncomplicated but uncontrolled NV leads to hospitalisations which increases the use of healthcare resources. Regardless of the underlying cause, NV increases socioeconomic cost and reduces the productivity of patient. A study concluded that the NVP often remains untreated or undertreated.
- the present invention provides choices of anti-emetic compositions, kits, and methods to suit various patient populations.
- the present invention has the advantage of providing flexibility to a subject experiencing NV to have a composition that treats NV at a time when a sedative or calmative effect is not required or to be avoided. For example, during work hours, when operating a machine or when attending to dependents, but also provides a composition that treats NV that further includes a sedative or calmative for assisting the subject to relax or fall asleep.
- the objective of the present invention is to achieve anti-nausea and anti-emetic effects via the actions of comprised ingredients on multiple pathophysiological mechanisms.
- the present invention provides compositions, kits, and methods that deliver anti-nausea and anti-emetic effects from at least two of the pharmacological approaches below: a. Suppressing receptors in the gastrointestinal tract, b. Suppressing receptors in the central nervous system (CNS), c. Reduction in oxidative stress (antioxidant properties), d. Addressing underlying vitamin B6 deficiency.
- Core ingredients of the present invention provide anti-nausea and anti-emetic properties by working on the same or different aspect of the pathophysiology of nausea and vomiting.
- Core ingredients of the present invention are; a. inactivated form(s) of vitamin B6, b. activated form(s) of vitamin B6, c. ginger in non-standardised forms, d. ginger in standardised form(s), e. sedative antihistamine(s).
- Vitamin B6 delivers anti-nausea and anti-emetic effect by reducing oxidative stress and 22 23 24 addressing underlying vitamin B6 deficiency ’ ’ .
- Vitamin B6 is one of the most central molecules in cellular metabolism. Nausea and/or vomiting can be a symptom of vitamin B6 deficiency because of various underlying reasons at the cellular level. Role of vitamin B6 extends to several metabolism processes.
- Vitamin B6 levels are reduced during the pregnancy, and hence vitamin B6 is helpful to
- Vitamin B6 is useful treatment option in other forms of nausea too. ’
- Amino acids are the building blocks of protein. Active co-enzyme or phosphorylated or also referred herein as the activated form of vitamin B6 plays the crucial role in the biosynthesis and degradation of amino acids. Neurotransmitters are required for communication in-between nerve cells and between nerve cells and other cells. Synthesis of these neurotransmitters requires enzymes. These enzymes use vitamin B6 as co-enzymes.
- Activation of vitamin B6 from an inactivated form is enzyme dependent. Considering the underlying cause of nausea, for some patients activated form of vitamin B6 could be more useful than the inactivated form of vitamin B6 or vice versa.
- the present invention provides compositions comprising one or more activated forms of vitamin B6 with or without one or more inactivated forms of vitamin B6.
- P5P Pyridoxal 5'-phosphate
- P5P increases antioxidant enzyme activities in post-surgery patients .
- P5P breaks down homocysteine and hence helps to improve nausea related to PCOS.
- Vitamin B6 plays positive role in glutathione reductase dependent antioxidant system and provides defence against free radicals .
- Alcohol consumption increases oxidative stress and is primary cause of nausea related to alcohol use. Oxidative stress contributes to inflammation of GI tract during gastroenteritis. Hence managing inflammation would help to manage nausea related to gastroenteritis.
- Ginger delivers anti-nausea and anti-emetic effect by suppressing receptors in the gastrointestinal tract and in the central nervous system (CNS) , and by reducing oxidative stress.
- CNS central nervous system
- the present invention delivers embodiments comprising ginger as in standardised and nonstandardised forms.
- Pharmacological actions in both the forms of ginger are from the constituents of ginger. Some constituents of ginger act on receptors in GI tract whereas some on the receptors of the CNS . Considering the cost and underlying cause of nausea, ginger in standardised forms may be more suitable than non-standardised forms or vice versa.
- Anti-cancer treatments triggers chemoreceptor trigger zones and results in higher expression of 5HT receptors 3 **. Hence antagonism of 5-HT receptors results in anti-nausea and anti-emetic effects. Research indicates that constituents of ginger have 5HT3 antagonistic activity . Constituents of ginger with smaller molecular weight such as 6-gingerol, 8-gingerol and 6-shogaol can penetrate the blood brain barrier 36 .
- the ginger acts peripherally, within the gastrointestinal tract, by increasing the gastric tone and motility due to anticholinergic and anti-serotonergic actions mainly due to action on serotonin (5-hydroxytryptamine, 5-HT3, and 5-HT4) and cholinergic (M3) receptor activities.
- Gingerol also has powerful anti-inflammatory and antioxidant effects and may help to reduce oxidative stress, which results from an excessive amount of free radicals in the body. Gingerols and shogaols have higher antioxidant properties .
- Sedative antihistamines deliver anti-nausea and anti-emetic effects via suppression of Hl receptors in the CNS and gut. Sedative antihistamines can also cross the blood brain barrier (BBB). Sedative antihistamines’ anti-nausea and anti-emetic effects are from their actions on receptors of vomiting centre after crossing the blood brain barrier, receptors of CTZ (also known as area postrema or AP) without crossing the BBB and receptors of the gut. Some sedative antihistamines have anticholinergic properties and ability to block muscarinic receptors in the CNS and gut. The sedating antihistamines also have a calmative, relaxant, and muscle relaxant properties.
- BBB blood brain barrier
- CTZ also known as area postrema or AP
- the sedating antihistamines used herein have an anti-emetic effect and are particularly useful for treating nausea and vomiting related to pregnancy, drugs induced, alcohol induced, motion sickness, gastroenteritis, PCOS, anti-cancer treatment and surgery. 38 ’ 39 ’ 40 ’ 41 ’ 42 '
- CTZ also known as area postrema (AP) is located outside the blood brain barrier, within the dorsal surface of medulla oblongata, on the floor of the fourth ventricle of the brain.
- Emetic agents in the blood are detected by the receptors present in the CTZ which induces vomiting.
- the present invention provides compositions with ingredients that acts on receptors of CNS including receptors of CTZ (without crossing the BBB), receptors of vomiting centre (after crossing the BBB).
- Chemoreceptor trigger zone contains dopamine (D2), serotonin (5-HT3), muscarinic (Ml), histamine (Hl), opioid and NK1 receptors.
- Vestibular centre contains histamine (Hl) and muscarinic (Ml) receptors, serotonin (5-HT3), dopamine (D2) and NK1 receptors.
- Vomiting centre contain serotonin (5-HT3) and muscarinic (Ml) receptors.
- GI track nerves (and other periphery nerves) contains serotonin (5-HT3), dopamine (D2) and NK1 receptor.
- the present invention delivers synergistic and/or additive anti-nausea and anti-emetic effects by combining Hl receptor antagonists (sedative antihistamines), muscarinic receptor antagonists (promethazine, doxylamine, diphenhydramine, dimenhydrinate, (6)-gingerol, (8)-gingerol, (10)- gingerol, and (6)-shogaol), dopamine receptor antagonists (promethazine, dimenhydrinate), cholinergic receptor antagonists (promethazine, cyclizine, dexchlorpheniramine, dimenhydrinate), 5-HT antagonists (promethazine, (6)-gingerol, (8)-gingerol, (lO)-gingerol, and (6)-shogaol), Neurokinin 1 (NK1) antagonists ((6)-gingerol, (8)-gingerol, (lO)-gingerol, and (6)-shogaol), and antioxidants (activated and inactivated B6, ginger
- the present invention relates to a pharmaceutical composition for the prevention, treatment, and management of nausea, vomiting, or combination thereof, comprising:
- the gingerols, shogaols, paradols, or combination thereof present in an amount in the range of 0.5mg to 300mg
- the pyridoxal 5 ’-phosphate is present in an amount in a range of Img to 200mg
- the one or more sedative antihistamine(s) is present in an amount in a range of 0.5mg to 200mg.
- the gingerol is selected from the group consisting of (6)-gingerol, (8)-gingerol, (lO)-gingerol, (6)-gingerdione, (6)-gingerdiol, (6)-gingerdiol diacetate, (6)-ginger sulphonic acid, 6)-demethoxygingerol, (6)-methylgingerol, or combination thereof;
- the paradol is (6)-paradol, (8)-paradol, (lO)-paradol, or combination thereof;
- the shogaol is (6)- demethoxyshogaol, (6)-shogaol, (8)-shogaol, (10) shogaol, (6)-methylshogaol, (6)-hydroxyshogaol, (6)-dehydroshogaol, or combination thereof and one or more pharmaceutically acceptable salt(s), metabolite(s), analog(s),
- the pharmaceutical composition further comprises pyridoxal, pyridoxamine, pyridoxine 5' phosphate and pyridoxamine 5' phosphate.
- the one or more sedative antihistamine is shortacting, long-acting, intermediate-acting, or combination thereof.
- the one or more sedative antihistamine is selected from the group consisting of doxylamine and salt thereof, dexchlorpheniramine and salt thereof, diphenhydramine and salt thereof, dimenhydrinate and salt thereof, chlorpheniramine and salt thereof, brompheniramine and salt thereof, pheniramine and salt thereof, hydroxyzine and salt thereof, cyproheptadine and salt thereof, carbinoxamine and salt thereof, pyrilamine and salt thereof, tripelennamine and salt thereof, phenindamine and salt thereof, trimeprazine, and salt thereof, cyclizine and salt thereof, promethazine and salt thereof, phenyltoloxamine and salt thereof, cyproheptadine and salt thereof, alimemazine and salt thereof, clemastine and salt thereof, ketotifen and salt thereof, mepyramine and salt thereof, antazoline and salt thereof, orphenadrine and salt thereof, bromazine and salt
- the salt is selected from the group consisting of succinate, maleate, esters, amines, hydrochloride, phosphate, calcium phosphate, or dihydrochloride.
- the present invention relates to a pharmaceutical composition for the prevention, treatment, and management of nausea, vomiting, or combination thereof comprising of:
- the composition further comprises other ingredients such as caffeine, antioxidants (e.g. glutathione, reduced glutathione), one or more forms of iron, vitamin A (e.g., retinol acetate), one or more forms of vitamin B12, vitamin B3, alpha-lipoic acid (R or S form), one or more forms of vitamin C, alpha tocotrienol, coenzyme Q10 (activated or inactivated), ubiquinol, zinc, selenium, magnesium citrate, magnesium glycinate, and magnesium chelates, Hl antagonists; H2 antagonists; proton-pump inhibitors, analgesics (paracetamol); flavin mononucleotide (FMN, also known as riboflavin-5-phosphate or R5P), metabolites of riboflavin; folinic acid; 5-MTHF; folic acid; probiotics; or combination thereof.
- antioxidants e.g. glutathione, reduced glutathione
- vitamin A e.g.
- lactose, gluten or dairy-derived excipients are excluded.
- one, more or all pharmaceutical composition(s) are modified to release the ingredients at a specific location of the body and/or at a specific rate and/or for a specific time duration.
- the present invention relates to kit for the prevention, treatment, and management of nausea, vomiting, or combination thereof comprising:
- the kit is designed or presented with the indicia distinguishing the first and second pharmaceutical composition from each other, dosage instructions for a specific medical condition, instructions for coordinating the administration of each pharmaceutical composition wherein;
- the first pharmaceutical composition is to administer during a particular time and/or at specific time interval(s) of the day or over 24 hrs period or an event, when sedation or sleep is desirable or not contraindicated, or
- the first or second pharmaceutical composition is to administer during a particular time and/or at specific time interval(s) of the day or over 24 hrs period or an event, when sedation or sleep is not desirable or not expected or contraindicated
- the container that incorporates the kit includes the indicia, the instructions, and a plurality of first and second pharmaceutical compositions, wherein the kit is designed for ‘day and night’ use and/or is presented as a kit comprising ‘drowsy’ and/or ‘non-drowsy’ pharmaceutical compositions, wherein the first pharmaceutical composition is administered with or without the second pharmaceutical composition, and wherein the kit is designed or presented to provide access to each pharmaceutical composition, the indicia distinguishing each pharmaceutical composition from each other, dosage instructions related to a specific medical condition, instructions for coordinating the administration of each pharmaceutical composition for the duration of one to four weeks or a month.
- each pharmaceutical composition present therein comprises a different sedative antihistamine and/or dose of each sedative antihistamine is different in each pharmaceutical composition present therein.
- the pharmaceutical composition or kit is prepared in a compounding pharmacy or in a facility approved by the relevant authority of the local jurisdiction to manufacture therapeutic preparation.
- the present invention relates to a method of prevention, treatment, and management of nausea, vomiting or combination thereof comprising administering the therapeutically effective amount of the pharmaceutical composition and kit as claimed in claims 1 to 15 to a subject in need thereof.
- the present invention relates to a pharmaceutical composition and kit for use in the manufacture of medicament for the prevention, treatment, and management of nausea, vomiting or combination thereof.
- the present invention relates to a use of the pharmaceutical composition for the prevention, treatment, and management of nausea, vomiting or combination thereof.
- compositions, kits and methods comprising one or more of the core ingredients to achieve the objective described herein.
- compositions, kits and methods of the present invention comprises;
- the present invention relates to a pharmaceutical composition for the prevention, treatment, and management of nausea, vomiting or combination thereof comprising of:
- the present invention relates to a pharmaceutical composition for the prevention, treatment, and management of nausea, vomiting or combination thereof comprising of:
- the present invention relates to relates to a pharmaceutical composition for the prevention, treatment, and management of nausea, vomiting or combination thereof comprising of:
- activated form(s) of vitamin B6 is selected from the group consisting of pyridoxal 5 ’-phosphate, pyridoxine 5' phosphate and pyridoxamine 5' phosphate; also known as P5P or PLP, PNP, PMP respectively, and/or one or more pharmaceutically acceptable salt(s), metabolite(s), analog(s), polymorph(s), isomer(s), prodrug(s), solvate(s), hydrate(s), or derivative(s) thereof.
- PLP also referred as pyridoxal 5’-phosphate, P5P
- inactivated form(s) of vitamin B6 is selected from the group consisting of pyridoxine and/or salts thereof, pyridoxal and/or salts thereof, pyridoxamine and/or salts thereof, also known as PYN, PYL, PYM respectively, and/or one or more pharmaceutically acceptable salt(s), metabolite(s), analog(s), polymorph(s), isomer(s), prodrug(s), solvate(s), hydrate(s), or derivative(s) thereof.
- an inactivated form of B6 is pyridoxine hydrochloride (pyridoxine HCL).
- activated and inactivated forms of vitamin B6 may be presented in any combination, such as but not limited to, PNP+PMP, PNP+PLP, PMP+PLP, PMP+PNP+PLP, PYL+PNP+PMP, PYM+PNP+PMP, PYL+PNP+PLP, PYM+PNP+PLP, PYL+PMP+PLP, PYM+PMP+PLP, PMP+PNP+PLP+PYL, PYM+PMP+PNP+PLP etc, or salt(s) thereof.
- the combination of activated and inactivated forms is pyridoxal 5 ’-phosphate and pyridoxine HCL.
- one or more pharmaceutically acceptable salts including for example and without limitation; esters, amines, hydrochloride, phosphate, calcium phosphate, or dihydrochloride of pyridoxine, pyridoxal, and pyridoxamine.
- ginger in non-standardised forms can be powder, extract or any other form of mixture that is derived from one or more parts of the ginger plant, including, but not limited to leaves, root, rhizome, or stems, either from the same or different species from the family of Zingiberaceae, cultivated in any region of the world.
- Standardisation of ginger herein means the process of establishing a set of quantitative parameters for the chemical compositions to ensure quantitative values for the assurance of definitive qualitative and quantitative values to achieve efficacy, safety and reproducibility. Furthermore, because constituents of ginger have different biological properties, the present invention, considering the indication and desired pharmacological action, comprises constituents of ginger in standardised form(s) to ensure the minimum quantity of specific constituents and/or constituents from one or more 'chemical groups'.
- standardisation by chemical group(s) means quantitative standardisation for the constituents that share the same chemical group(s).
- quantitative standardisation of constituents from the gingerols and/or shogaols group(s) to ensure that an embodiment contains at least a specific amount of chemical constituents from a ‘gingerols’ and/or ‘shogaols’ and/or ‘paradols’ group(s).
- Embodiments may be standardised for only one group of constituents, i.e., standardisation for only ‘gingerols’ group of constituents, standardisation of only ‘shogaols’ group of constituents, standardisation of only ‘paradols’ group of constituents.
- Embodiments may be standardised for one or more individual constituents, i.e., standardisation for only (6)-gingerol, standardisation for the total quantity of (6)-gingerols and (6)-shogaols, standardisation for only (6)-gingerol, standardisation for the total quantity of (6)-gingerol, (8)-gingerol and (lO)-gingerol, standardisation for only (6)-shogaol, standardisation for the total quantity of (6)- shogaol, (8)-shogaol and (lO)-shogaol.
- Embodiments may be standardised for one constituent and 'chemical group(s)' i.e., standardisation for (6)-gingerol and shogaols.
- ginger in standardised form is a mixture of constituents present in ginger, and these constituents are selected from the group consists of, including, but not limited to, (6)- gingerol, (8)-gingerol, (lO)-gingerol, (6)-gingerdione, (6)-gingerdiol, (6)-gingerdiol diacetate, (6)- ginger sulphonic acid, (6)-paradol, (8)- paradol, (lO)-paradol, (6)-demethoxygingerol, (6)- methylgingerol, (6)-demethoxyshogaol, (6)-shogaol, (8)-shogaol, (10) shogaol, (6)-methylshogaol, (6)- hydroxyshogaol, (6)-dehydroshogaol, 2-propyl-5(-(3-methoxy-4- hydroxyphenyl)ethyl)
- standardised forms of ginger constituents are (6)-gingerol, (8)- gingerol, (lO)-gingerol, (6)-shogaol, (8)-shogaol, (10) shogaol, (6)-paradol, (8)- paradol, (lO)-paradol, or more pharmaceutically acceptable salt(s), metabolite(s), analog(s), polymorph(s), isomer(s), prodrug(s), solvate(s), hydrate(s), or derivative(s) thereof.
- standardised forms of ginger are standardised for one or more groups of constituents of the ginger such as, including but not limited to gingerols, shogaols, hexahydrocurcumin, and its derivatives (curcuminoids), zingerones, gingerenones, gingerdiones, gingerdiols, paradols, gingeroneA, diarylheptanoids.
- standardised forms of ginger are standardised by gingerols, shogaols, paradols groups of constituents.
- one or more sedative antihistamines are selected from the group consisting of doxylamine and salt thereof, dexchlorpheniramine and salt thereof, diphenhydramine and salt thereof, dimenhydrinate and salt thereof, chlorpheniramine and salt thereof, brompheniramine and salt thereof, pheniramine and salt thereof, hydroxyzine and salt thereof, cyproheptadine and salt thereof, carbinoxamine and salt thereof, pyrilamine and salt thereof, tripelennamine and salt thereof, phenindamine and salt thereof, trimeprazine, and salt thereof, cyclizine and salt thereof, promethazine and salt thereof, phenyltoloxamine and salt thereof, cyproheptadine and salt thereof, alimemazine and salt thereof, clemastine and salt thereof, ketotifen and salt thereof, mepyramine and salt thereof, antazoline and salt thereof, orphenadrine and salt thereof, bromazine and salt thereof, de
- doxylamine and salt thereof Preferably, doxylamine and salt thereof, promethazine and salt thereof, diphenhydramine and salt thereof, dimenhydrinate and salt thereof, dimenhydrinate and salt thereof, and dimenhydrinate and salt thereof, and levomepromazine and salt thereof.
- the one or more sedative antihistamine is present in an amount in a range of 0.5mg to 200mg per unit dose.
- the gingerols, shogaols, paradols or combination thereof present in an amount in the range of 0.5mg to 300mg per unit dose.
- Pyridoxal 5 ’ -phosphate is present in an amount in a range of Img to 200mg.
- Embodiments may include any short-acting antihistamine combined with a long-acting antihistamine.
- Caffeine may be present in any aspect of the present invention to treat NV to counterbalance the sedation effect of one or more antihistamines.
- Embodiments may include other antioxidants, including but not limited to, glutathione, reduced glutathione, vitamin A (e.g., retinol acetate), one or more forms of vitamin B12, vitamin B3, alpha-lipoic acid (R and/or S form), one or more forms of iron, one or more forms of vitamin C, alpha tocotrienol, coenzyme Q10 (activated or inactivated), ubiquinol, zinc, selenium, magnesium citrate, magnesium glycinate, and magnesium chelates or any other forms thereof.
- vitamin A e.g., retinol acetate
- vitamin B12 e.g., retinol acetate
- R and/or S form alpha-lipoic acid
- iron one or more forms of iron
- one or more forms of vitamin C alpha tocotrienol
- coenzyme Q10 activated or inactivated
- ubiquinol zinc, selenium, magnesium citrate, magnesium glycinate
- Flavin mononucleotide also known as riboflavin-5-phosphate or R5P
- R5P riboflavin-5-phosphate
- PLP pyridoxal5'-phosphate
- Embodiments described herein may be given with FMN, folinic acid, 5-MTHF, and folic acid either in a single unit or separate unit doses.
- Embodiments may include probiotics with or without prebiotic to achieve the same objective.
- the ‘active ingredients’ or ‘core ingredients’ used in the present invention can be used as pharmaceutically acceptable salt(s), metabolite(s), analog(s), polymorph(s), isomer(s), prodrug(s), solvate(s), hydrate(s), or derivative(s) thereof.
- kits and methods for prevention, treatment and management of nausea and vomiting comprising one or more dosage units each comprising one or more of:
- sedative antihistamine(s) indicia distinguishing all comprised dosage units from each other; indicia distinguishing sedative dosage units causing sedation from the non-sedative dosage units; indicia distinguishing sedative dosage units for administration during a particular time of the day or event when sedation or sleep is desirable or not contraindicated; indicia distinguishing non-sedative dosage units for administration during a particular time of the day or event when sedation or sleep is not desirable or contraindicated; wherein instructions are provided for coordinating the administration of each dosage unit as a treatment regimen whereby a dosage unit is for administration during a particular time of the day or event; wherein a container or packaging that incorporates the indicia, the instructions and a plurality of each dosage units; wherein a blister card individually and releasably containing the unit doses; wherein said dosage units are arranged horizontally or vertically in order of their use across the blister card.
- the invention provides kits for promoting the proper sequential oral administration of pharmaceutically active ingredients.
- kits and methods may have one or all features described herein.
- active ingredients may be free form, in various salt forms, various hydration states, etc. If, for example, a different salt form of an active ingredient is used in the invention, the skilled person will understand that the amount will need to be adjusted in accordance with the molecular weight.
- 'Unit dose' or 'unit dosage' herein is a dosage form comprising an amount of therapeutically active ingredients suitable for administration in one single dose.
- compositions, kits and methods comprising active ingredients in a range of doses considering the severity of nausea and vomiting, medical conditions, age, and underlying cause.
- the dose range of each ingredient is described herein.
- the dose range is for a unit dose.
- the present invention is not limited to these dose ranges.
- the dose of the comprised ingredient can be less or more than the described herein to achieve desired anti-nausea and anti-emetic effects.
- a) Doxylamine may be present in any aspect of the invention described herein at an amount per unit dose of about 0.5mg to 200 mg.
- b) Diphenhydramine may be present in any aspect of the invention described herein at an amount per unit dose of about 0.5mg to 200 mg.
- Dimenhydrinate may be present in any aspect of the invention described herein at an amount per unit dose of about 0.5mg to 300mg.
- Promethazine may be present in any aspect of the invention described herein at an amount per unit dose of about 0.5mg to 200mg.
- Cyclizine may be present in any aspect of the invention described herein at an amount per unit dose of about 0.5mg to 200mg.
- Levomepromazine may be present in any aspect of the invention described herein at an amount per unit dose of about 0.5mg to lOOmg.
- Dexchlorpheniramine may be present in any aspect of the invention described herein at an amount per unit dose of about 0.5mg to 25mg.
- Ginger in non-standardised forms may be present in any aspect of the invention described herein at an amount per unit dose of about 100 mg to 2000mg or equivalent thereby.
- Ginger extract in standardised forms may be present in any aspect of the invention described herein at an amount per unit dose of about 2mg to 2000mg.
- gingerols, shogaols, paradols, or combination thereof may be present in any aspect of the invention described herein at an amount per unit dose of about 0.5mg to 300 mg
- Pyridoxine may be present in any aspect of the invention described herein at an amount per unit dose of about Img to 200mg.
- Pyridoxal 5 ’-phosphate may be present in any aspect of the invention described herein at an amount per unit dose of about Imgto 200mg.
- Kits or methods can be designed using this unit dose ranges to achieve the same objective.
- the present invention extends to any compositions, kits and methods recognised by one skilled in the art to achieve the effective concentration of one or more comprised ingredients to treat NV.
- a compound or active agent or active ingredient or core ingredient is present in a composition or in combination, in an amount effective to provide the desired therapeutic or physiological effect or outcome.
- This effect may be the treatment, alleviation, diminishment, or amelioration of nausea and/or vomiting.
- Undesirable effects e.g., side effects, are sometimes manifested along with the desired therapeutic effect; hence, a practitioner balances the potential benefits against the potential risks in determining an appropriate ‘effective amount’.
- the exact amount required will vary from subject to subject, depending on the species, age, medical condition, and general condition of the subject, mode of administration and the like. An appropriate ‘effective amount’ in any individual case may be determined using routine experimentation by one skilled in the art.
- the specific dose level for any patient will depend upon a variety of factors, including the activity of the specific composition employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination (i.e., other drugs being used to treat the patient), and the severity of the particular disorder.
- drug combination i.e., other drugs being used to treat the patient
- patient dosage may be adjusted by adjusting the number of fixed doses, for example, by changing the number of tablets taken or by adjusting the timing for the next dose.
- the present invention provides compositions, kits, and methods for preventing, treating, and managing NV related to pregnancy, drug use, alcohol use, motion sickness, gastroenteritis, PCOS, anti-cancer and surgery.
- Embodiments may be used to achieve any desired outcome, including but not limited to minimal reduction to complete elimination of nausea and/or vomiting any time prior, during or after episode of nausea and/or vomiting related to pregnancy, drug use, alcohol use, motion sickness, gastroenteritis, PCOS, anti-cancer and surgery.
- Embodiments may be used to design a kit or a method in combination with other anti-nausea and/or anti-emetic treatments. Depending on the objective and indication(s), which can be prevention, treatment or management, amount of the comprised ingredient may vary in embodiments.
- Embodiments may be used to design kits or methods combined with other pharmacological or non-pharmacological interventions to achieve the same objective.
- Embodiments of the present invention may be administered by a patient, a healthcare professional or a carer in a hospital, home, or caring facility.
- Embodiments may be prepared in a community, hospital pharmacy, or facility approved by the relevant authority to manufacture therapeutic preparation for human or non-human use.
- embodiments of the present invention may be used during the first, second or third trimester of the pregnancy to achieve the desired outcome, including but not limited to minimal reduction to complete elimination of nausea and/or vomiting for any particular time of the day, throughout the day or every day during the pregnancy.
- Embodiments may be used as single or multiple dosage forms or to design a kit or a method to achieve the desired outcome for the pregnant woman.
- Embodiments may be used to design a kit, or a method combined with ingredients such as folinic acid, 5-MTHF, folic acid, multivitamins; or may be combined with any other anti-nausea or anti-emetic treatments.
- embodiments may be designed in combination with analgesics, benzodiazepines, other anti-emetics, anti-psychotics, or naloxone for the NV related to drug use or overdose.
- embodiments may be designed comprising core ingredients of the present invention combined with non-sedative antihistamines and/or antioxidants for the prevention, treatment, and management of nausea and/or vomiting and/or facial flushing and/or erythema and/or hangover associated with alcohol use or overdose.
- embodiments of the present invention may be used prophylactically to prevent the occurrence of motion sickness.
- Prophylactic use of embodiments is preferably within 2 hrs, 15 to 30 minutes more preferred, before expected symptoms.
- embodiments may be combined with anti-diarrhoeal, rehydration salts or antibiotics.
- kits and/or methods can be used on an ad-hoc basis or designed to meet a patient’s requirements on one or more particular day(s) of the menstrual cycle.
- Embodiments may be designed with coenzyme Q10 (activated or inactivated), ubiquinol, folinic acid, folic acid or 5-MTHF (methylfolate).
- cancer herein meaning any form of abnormal growth of cells in a subject.
- Anti-cancer treatment herein means all current and future treatments to prevent, treat and manage cancer and is not limited to chemotherapy, radiation, immunotherapy, stem cell transplant, surgery, targeted therapy, hormone therapy, pharmacological or non-pharmacological interventions.
- Embodiments of the present inventions may be used for nausea and vomiting induced by mild, moderate, or highly emetogenic anti-cancer treatment regimens.
- Embodiments may be used as single or multiple dosage forms or to design a kit or a method to achieve the desired outcome for the patient being treated for cancer.
- Embodiments may be used or administered immediately, several seconds, hrs, days, or weeks prior to the treatment and/or during the treatment and/or after immediately, several seconds, hrs, days or weeks from initiation of the treatment.
- embodiments may be designed in combination with other 5HT3 antagonists, metoclopramide, prochlorperazine, analgesics, anaesthetic agents considering age, type of surgery and patient history.
- the analgesics is paracetamol.
- the nausea or vomiting treated is one described herein, in both acute and chronic forms, for example, but not limited to, pregnancy, drug use, alcohol use, motion sickness, gastroenteritis, PCOS, anti-cancer treatment, and surgery, fibromyalgia, digestive disorders (gastritis, gastroparesis, gastroesophageal reflux disease, IBS, celiac disease, gallbladder conditions, pancreas conditions, gallstones, intestinal ischemia, intestinal obstruction, intracranial hematoma, intussusception (in children), irritable bowel syndrome, inflammatory bowel disease (crohn’s, ulcerative colitis), pancreatitis (pancreas inflammation), peptic ulcer, pseudotumor cerebri, pyloric stenosis (in infants), gastroparesis or slow stomach emptying, bowel obstruction, retch, (inflammation of the
- the present invention is used for NV related to pregnancy, drug use, alcohol use, motion sickness, gastroenteritis, PCOS, anti-cancer treatment and surgery.
- a subject in need of treatment is one experiencing or expecting to experience nausea and/or vomiting.
- the subject may have been diagnosed with NV and/or recommended anti-emetic and/or antinausea treatment by a doctor, pharmacist, nurse, mid-wife, or any health care professional. NV may also be self-diagnosed.
- ‘treating’ or ‘treatment’ means reducing, ameliorating, or providing relief from NV before or after its onset. It also includes ameliorating the severity, incidence, progression, or duration of NV experienced by a subject. As compared with an equivalent untreated control, such amelioration or relief is at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, or 100%, as measured by any biochemical or clinical measurement that may be measured by using standard medical methods of evaluating and scoring NV. The benefit to a subject to be treated is either statistically significant or perceptible to the patient or the physician.
- treatment encompasses both disorder-modifying treatment and symptomatic treatment, either of which may be prophylactic, i.e., before the onset of symptoms, in order to prevent, delay or reduce the severity of symptoms, or therapeutic, i.e., after the onset of symptoms, in order to reduce the severity and/or duration of symptoms.
- the subject also referred to as patient herein may include but are not limited to primates, especially humans, domesticated companion animals such as dogs, cats, horses, and livestock such as cattle, pigs, sheep.
- compositions comprise one or more excipients required to prepare formulation for therapeutic use.
- Excipients are extra materials that are added to the active ingredients to prepare a dosage form.
- Pharmaceutically acceptable excipients including for example and without limitation; one or more binders, adhesives, lubricants, diluents, fillers, coating agent, antiadherent, humectants, preservatives, antioxidants, buffering agents, flavouring agents, bulking agent, colouring agents, sweetening agents, plasticisers, solvent and co-solvent, organic solvents, topical solvents, sorbents, glidants, chelating agents, granulating agent, taste masking agent, thickening agents, disintegrants, plasticisers, solubilizer or solubility enhancer, any carrier oil, coatings, barrier layer formulations, surface active agents, viscosity imparting agents, viscosity increasing agent, stabilising agent, suspending agents, emulsifying agents, viscosity adjusters
- Formulations may comprise microcapsules or gelatine-microcapsules, liposomes, albumin microspheres, microemulsions, nanoparticles or nano capsules.
- the formulation may contain one or more electrolytes. It also extends to formulation changed to reduce the size of the unit dose being administered.
- compositions herein refers to any excipient that does not interfere with the effectiveness of the biological activity of comprised active ingredients and is not contra-indicated, non-toxic and non-teratogenic, i.e., not harmful to a subject and embryo or foetus of a subject.
- Dosage forms may be presented as flavoured dosage, unflavoured, or flavour free. This invention may be presented in any combinations and pharmaceutically acceptable dosage forms. Dosage forms of the present invention may include various forms of release, which include but are not limited to immediate release, extended-release, variable release, controlled release, dissolution- controlled release, sustained release, dual release, delayed-release, long-acting, osmotically controlled release, monolithic dosage forms, multi -particulate forms, and combinations thereof. It can be presented in formulations designed to achieve the shortened and/or extended half-life of the individual ingredients comprised in this invention.
- dosage forms may include one or more oral dosage forms as listed here but not limited to tablets, compressed tablets, enteric -coated tablets, controlled release tablets, film-coated tablets, effervescent tablets, reconstitute powders, capsules, soft gelatine capsules, hard gelatine capsules, caplets, multi-layer/dual layer capsule, bi-layer capsule, capsules may encapsulate a powder, liquid, or gel, quick dissolve tablets, multilayer tablets, bi-layer tablets, orally disintegrating tablets, powders, granules, dispersible granules, tablet/capsule combinations, coated core tablets, multi-layered with or without dual release or palletised form. It may be formulated containing ion exchange resins or formulations using responsive polymers.
- Embodiments may be provided, including for example and without any limitation, in the form of lollipops, wafer, bars, sticks, chewable tablets, buccal films, gummies, troches, lozenges, chewable lozenges, beads, bite capsules, mouth soluble or dispersible forms like suckable, eatable, chewable coherent forms, biscuits, cereals, confections, cachets, douches, health bars, patches etc.
- Compounds may be formulated for any appropriate route of administration including for example and without limitation, as oral preparations (solutions, emulsions, suspension, elixirs, syrups, etc.), topical preparations (nasal drops, nebulisers and inhalers, inhalants, pastes, creams and ointments for skin application, gels, lotions, creams, foams, powders, pessaries for vaginal administration etc.), sublingual and buccal administration, rectal administration (suppositories and enemas), ocular, implants, depot implants, ingestible, parental drug administration (intradermal administration, implants, subcutaneous injection, intramuscular injection, intravenous injection, infusions, intramuscular, intraocular, periocular, intraorbital, spinal, intracranial, intrathecal, intrasynovial and intraperitoneal injection), as well as any similar injection or infusion or inhalation technique, solid dosage form and solid modified release form, semi-solid
- the present invention extends to any formulations designed to achieve release of comprised ingredient at a particular location of the subject and/or at any particular rate of release into the subject.
- the dosage formulation may be modified to achieve release of comprised ingredients at a specific location of the body and/or at any specific rate and/or for any specific time duration
- Typical modes of delivery for topical compositions include applying using the fingers, using a physical applicator such as cloth, tissue, swab, stick or brush, spraying including mist, aerosol or foam spraying, dropper application sprinkling, soaking, and rinsing.
- a physical applicator such as cloth, tissue, swab, stick or brush
- spraying including mist, aerosol or foam spraying, dropper application sprinkling, soaking, and rinsing.
- compositions may be formulated as inhaled formulations, including sprays, mists, or aerosols and may be delivered via any inhalation methods known to a skilled person in the art. Such methods may include, for example including without limitation, metered-dose inhalers, nebulisers, multi-dose dry powder inhalers or any other conventional or novel inhalation methods.
- the dosage may be supplied in any pharmaceutically acceptable container listed here but not limited to blister packs, composite blister packs, bottles, tubes, canisters, sachets, packets, child-resistant packaging, heat resistance packaging, light resistance packaging, moisture resistance, travelling kit, daily doses packaging, weekly or monthly dose packing, roll on etc.
- the composition described herein may be presented in individual packaging, day/night combination, composite packaging, packing designed and/or marked to differentiate the unit dose to make it more suitable and/or compliant for any indication and/or any age group and/or any individual subject.
- Embodiments may be combined with other pharmacological or non-pharmacological interventions for the prevention, treatment and management of nausea and vomiting.
- This invention extends to formulations and packaging changed to meet the requirements of particular demographics and/or to obtain regulatory approval from relevant authorities.
- 'daily' herein refers to administering one or more than one dose of the same or different ingredients within the 24-hr period or within the same day.
- a single daily blister card may include multiple doses to be taken in a 24-hour period.
- Embodiments of the invention may be designed with specific storage requirements in order to preserve comprised constituents.
- compositions, kits, and methods comprising gingerols and shogaols may be designed with storage requirements to store such embodiments at temperature in the range of -20 to 8 °C.
- Embodiments may be designed with instructions for compounding or preparation prior to administration to the subject. Such instructions may be designed to suit patients, carers, or pharmacists. These embodiments may contain ingredients other than the core ingredients to prepare formulations to achieve the same objective.
- the tablet of the above composition is prepared by following the steps given below:
- Example 2 Orally Disintegrating Tablet / Sublingual tablet (Non-Drowsy Tablet)
- step 3 To the blend of step 3 add magnesium stearate and mix further for 3 minutes.
- step 3 To the blend of step 3 add magnesium stearate and mix further for 3 minutes.
- Embodiments may be designed after establishing the individual needs by means of genetic or biomarks or similar tests.
- Vitamin B-6 Benefits, dosage, food sources, and deficiency symptoms, [online] Available at: https://www.medicalnewstoday.com/articles/219662.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Alternative & Traditional Medicine (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Physiology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention provides compositions, kits, and methods containing therapeutically effective amount(s) of one or more ingredient(s) selected from the group comprised of: one or more activated form(s) of vitamin B6, one or more inactivated form(s) of vitamin B6, ginger in non-standardised forms, ginger in standardised form(s), one or more sedative antihistamine(s). In particular, the present invention has anti-nausea and anti-emetic effects from the pharmacological actions of the comprised ingredients into multiple pathophysiological mechanisms. In particular, the present invention provides synergistic and/or additive effects from two or more comprised ingredients.
Description
COMPOSITIONS, KITS, AND METHODS TO PROVIDE SYNERGISTIC AND/OR ADDITIVE EFFECTS FROM COMPRISED INGREDIENTS FOR THE PREVENTION, TREATMENT AND MANAGEMENT OF NAUSEA AND VOMITING
TECHNICAL FIELD
[01] The present invention relates to compositions, kits and methods for the prevention, treatment and management of nausea and vomiting with a known or unknown underlying cause, including but not limited to pregnancy, motion sickness, drug use, alcohol use, gastroenteritis, polycystic ovary syndrome, anti-cancer treatment and surgery.
BACKGROUND ART
[02] As used herein, ‘nausea’ refers to a sense of an urge to vomit, while ‘vomit’ is the oral expulsion of the gastrointestinal content. Nausea and vomiting (NV) could be acute or chronic. Nausea and vomiting are symptoms of an underlying condition such as pregnancy, motion sickness, drug use, alcohol use, gastroenteritis, polycystic ovary syndrome (PCOS), anti-cancer treatment and surgery. Nausea and vomiting are an outcome of stimulation of receptors in the CNS and gut through various mechanisms.
[03] Nausea and vomiting in pregnancy referred herein as NVP could be frequent or infrequent and may even last throughout the pregnancy in some women. It could be mild or severe to the extent that it may require frequent pharmacological and/or non-pharmacological interventions. Severe NVP is known as hyperemesis gravidarum and may require treatment in the hospital. Pathophysiology of NVP are hormones, neurotransmitters and receptors mediated.
[04] Drugs can trigger nausea, and/or vomiting in some patients, and it is subjective. Besides anticancer drugs, some other drugs may induce NV in some patients. Commonly known drugs that cause NV include anti-depressants, opioids, anti-inflammatories, contraceptives, hormone replacement therapy (HRT) drugs and anti-psychotics. Drug-induced NV generally occurs when new drug treatment is initiated and often goes away after several days of continuation of the drug. In some conditions, medication is necessary to prevent, treat and manage NV associated with a drug. Withdrawal of some medication can also cause NV.
[05] Alcohol in excess amount is a toxin for the body. Alcohol breaks down into acetaldehyde in liver and this process produces harmful chemical which causes inflammation in the gastrointestinal tract and could result into nausea or vomiting. Untreated vomiting can cause dehydration.
[06] Motion sickness, as the word describe, is the feeling of being sick because of a motion. Receptors in the CNS and gut are activated when the body struggles to adjust with the motion; the brain receives conflicting information from the inner ears, eyes and nerves. Common symptoms of motion sickness are nausea with or without vomiting. Travel sickness, seasickness, airsickness, train sickness are types of motion sickness. It can also be caused by swinging, bumping, rotation, deceleration movement and various reasons.
[07] Gastroenteritis is the gut inflammation caused by the virus, bacteria, fungi, parasites, toxins or drugs, sometimes referred as ‘stomach bug’, stomach flu or food poisoning. Besides nausea and vomiting, diarrhoea, stomach cramps, fever, and headaches are also symptoms of gastroenteritis.
[08] In Polycystic ovary syndrome (PCOS), levels of an amino acid named homocysteine remain high. High levels of homocysteine increase inflammation, oxidative stress and increase the risk of atherosclerosis and thrombosis. In addition, high homocysteine level causes nausea, vomiting and fatigue. Vitamin B6 plays an essential role in the breakdown of homocysteine.
[09] Chemotherapy-induced nausea and vomiting (CINV), also known as anti-cancer treatment induced nausea and vomiting (AINV), is triggered with various types of anti-cancer treatment. NV from anti-cancer treatment is mediated via CNS and gut neurotransmitters. AINV is anticipated in nearly all patients and is addressed by the oncologist.
[010] Nausea and vomiting related to surgery also known as Post-Operative Nausea and Vomiting (PONV), can occur due to exposure of drugs during the operation. Commonly used drugs during the operations are anaesthetics, opioids etc. In addition, fear to undergo the operation and uncertain outcomes of the operation can induce NV in some patients. Overall, PONV is the outcome of the interaction between the brain and gastrointestinal tract. Pathophysiology of PONV involves chemical interaction between vomiting centres, chemoreceptor trigger zone (CTZ) and middle ear.
[Oil] Regardless of the underlying cause, all forms of NV impact quality of life, and in the case of anti-cancer treatment, it may affect treatment plans, and/or the patient’s willingness to undergo or continue the treatment. In addition, severe vomiting can lead to dehydration. Hence, all forms of NV should be addressed appropriately and on time with available treatment options. The availability of
pharmaceutical products varies worldwide, which further affects treatment selections by the health care professional.
PRIOR ART
[012] US patent no. 20070048367 relates to a herbal composition for treating morning sickness and includes a mixture of vitamin B6, folic acid, ginger root extract, and red raspberry leaf.
[013] US patent no. US20170049759 & EP patent no. EP3337480 relates to transdermal delivery of doxylamine and pyridoxine. The formulation includes doxylamine or its salts, pyridoxine or its salts or its active metabolites, and a vehicle system wherein pharmaceutical compositions are liquid formulations, semisolid formulations, and polymer matrices for treatment of nausea and vomiting in general and pregnant women in particular.
[014] WO patent no 2000066082 & AU patent no. 2000049779 relates to anti-nausea compositions and methods. It discloses novel nutritional anti-nausea compositions, anti-emetic compositions, and methods of using the same. The compositions comprise a vitamin B6 compound or derivative thereof; an alkaline buffering agent, an acceptable coating agent; and wherein the vitamin B6 compound or derivative thereof is separated from the alkaline buffering agent by the said acceptable coating agent.
[015] US patent no. 6340695 relates to a rapid onset formulation, preferably in the form of an enteric- coated tablet, for a medicament comprising a synergistic duo of active ingredients, namely, doxylamine succinate and pyridoxine HC1, for the treatment of nausea and vomiting, especially, but not limited to, during pregnancy.
[016] US patent no. 20140314680 relates to a dual release oral dosage system/dosage form comprising an immediate release component/composition and a delayed-release component/composition comprising one or more of doxylamine, an analog thereof, a derivative thereof, a prodrug thereof, a metabolite thereof and/or a salt thereof, and one or more of pyridoxine, a salt thereof, a metabolite thereof and/or a salt of the metabolite for the prevention and/or treatment of nausea and vomiting in pregnancy (NVP).
[017] US patent no. 20140335176 relates to a delayed release formulation containing doxylamine succinate and pyridoxine hydrochloride as the active ingredients in a disintegrant-free formulation and processes for manufacturing the same.
[018] US patent no. 20160058709 relates to plurimodal release formulation of metabolites and salts of doxylamine and pyridoxine. The patent covers the formulation with these active ingredients as
component of enteric coating within the enteric-coated formulation comprising these active ingredients.
[019] Indian patent no. 202021002251 relates to a solid oral composition of doxylamine succinate, pyridoxine hydrochloride in combination with ginger powder as a natural extract as synergistic additive. It provides the solid oral composition in the form of granules/powder filled into sachets or compressed into tablets, especially chewable tablets for the treatment of nausea and vomiting.
[020] US patent no. 20110280976 relates to methods for making and using gingerols for treating nausea and emesis associated with cancer chemotherapy. The methods feature supercritical, critical and near-critical fluids with and without polar cosolvents.
[021] US patent no. 20110028436 relates to oral combination of vitamins for treating and preventing nausea and other disorders. The compositions comprise vitamins as active ingredients, including vitamin B6 and its metabolites, vitamin K, and vitamin C, and a method for treating nausea or morning sickness with the oral compositions.
[022] US patent no. 20130171279 relates to composition for reducing side- and after-effects of cancer treatment. It includes three core components: whey protein, hepatoprotectant and/or nephroprotectant agents and, anti-emetic agent(s) such as ginger and/or peppermint.
[023] US patent no. 20100291057 relates to a composition for reducing oxidative stress and/or side effects occurring during cancer chemotherapy or improving a nutritional status during cancer chemotherapy. The composition comprises the following components (a) to (f): (a) an antioxidant agent; (b) at least one component selected from the group consisting of vitamin Bl, vitamin B2, vitamin B6, niacin, and pantothenic acid; (c) at least one component selected from the group consisting of folic acid, vitamin B12, and vitamin A; (d) zinc; (e) selenium; and (f) coenzyme Q10.
[024] WO patent no. 1986002553 is a nasal administration of known anti-nausea and anti-emetic therapeutic agents and dosage forms which discloses the use of selected antihistamines, anticholinergics, piperazines, phenothiazines, substituted butyprophenes and metoclopramide.
[025] US patent no. 4624965 relates to novel method of administering anti-nausea and anti-emetic agents and to novel dosage forms which includes the use of brompheniramine, promethazine, cyproheptadine, dimenhydrinate, meclizine, cyclizine, chlorcyclizine, buclizine, trimethobenzamide, benzquinamide metoclopramide, diphenhydramine, doxylamine, methapyrilene and tripelennamine for nasal administration.
[026] US patent no. 20200113856 relates to a compounded non-prescription medication for the treatment of motion sickness. The medication comprises: at least one analgesic selected from the group consisting of acetaminophen, ibuprofen, naproxen and salicylates; at least one histamine H2-receptor antagonist selected from the group consisting of nizatidine, famotidine, cimetidine, ranitidine, famotidine; and at least one antacid selected from the group consisting of calcium carbonate, sodium bicarbonate, magnesium hydroxide, aluminum hydroxide, and bismuth subsalicylate. It may optionally comprise at least one additional ingredient selected from the group consisting of spearmint extract and ginger extract.
[027] US patent no. 08137709 relates to fast-acting nausea formula which comprise of ginger root, gelatin, a fruit flavouring, and mint.
[028] CN patent no. 106492159 relates anti-motion sickness drug which discloses the use of fresh ginger, fructusamomi, orange peel, chrysanthemum, and wild jujube.
[029] Sedative antihistamines such as doxylamine, promethazine, dexchlorpheniramine, cyclizine, diphenhydramine, dimenhydrinate is present in several products. Many formulations are available containing metoclopramide, prochlorperazine, ondansetron, and are used worldwide for NV.
[030] Vitamin B6 is included in treatment guidelines by several health authorities worldwide to prevent, treat, and manage NVP. In addition, a product called Elevit morning sickness tablets containing vitamin B6, and ginger is available without prescription in Australia and is being marketed for NVP.
[031] A fixed-dose combination of doxylamine succinate (20mg) and vitamin B6 (20mg pyridoxine hydrochloride) is being marketed under the brand name Bonjesta® in the USA for the management of NVP in women who have not improved with the change in diet or other non-medicine treatments.
[032] Diclectin®, a combination of 10 mg doxylamine succinate and 10 mg vitamin B6 (pyridoxine hydrochloride) in a delayed-release tablet formulation, is available in Canada for women who have not benefited from the other therapies.
[033] Anti-emetics currently used for AINV include dopamine receptor antagonists such as metoclopramide, prochlorperazine, promethazine and haloperidol; serotonin (5HT3) receptor antagonists such as granisetron, ondansetron, palonosetron, tropisetron; neurokinin- 1 receptor antagonists (NK1 RA) such as aprepitant, netupitant. Other anti-emetics used in AINV are dexamethasone (a steroid), olanzapine (for their inhibitory effects on 5HT3 and dopamine receptors) and cannabinoids (not commonly used). Combination treatment options for AINV currently available
contain netupitant (NK1 receptor antagonist) and palonosetron (5HT3 antagonist) - marketed under the brand name akynzeo.
[034] Products containing scopolamine named hyoscine hydrobromide are currently available as a single ingredient under the brand name Kwells® and Travacalm HO®. In addition, Hyoscine combined with dimenhydrinate (sedative antihistamine) is available under the brand name Travacalm Original® to prevent and treat motion sickness.
[035] Doxylamine succinate 25 mg is available as ‘Pharmacist Only Medication’ for the temporary relief of insomnia or sleeplessness.
PROBLEMS IN PRIOR ART
[036] The present invention is an improvement over the prior art in that it delivers the compositions, kits, and methods for the prevention, treatment, and management of NV via the pharmacological actions of the comprised ingredients into multiple pathophysiological mechanisms involved.
[037] Currently, available treatment options for nausea and vomiting are relatively more expensive to the patient, not easily accessible, and have poor product availability.
ANTIHISTAMINE
[038] Prior-art (Restavit , Phenergan , Polaramine ) products with only sedative antihistamine as anti-emetic ingredient increase sedation when administered at higher doses to achieve a higher antiemetic effect. The present invention provides compositions, kits, and methods that do not have the same disadvantage because these compositions achieve a higher anti-emetic effect with the lower dose of antihistamine via synergistic and/or additive effect of other comprised ingredients. Unlike other prior arts, the present invention also provides compositions, kits and methods that enable the use of sedative antihistamines when sleep is desirable.
[039] Prior art (Restavit®, Phenergan®, Polaramine®) products containing sedative antihistamine are ‘Pharmacist Only Medicine’. These products either do not have treatment of NV as an approved indication or has a warning statement on the packaging indicating possible harm if used during pregnancy1. Hence, the refusal by the pharmacist for the supply of these products for the treatment of NVP is common.
[040] No commercial product exists in Australia with a dose of doxylamine less than 25mg. It is being marketed only for ‘temporary relief of sleeplessness’ with warnings on the product packaging
indicating safety concerns when used during pregnancy though doxylamine is listed as a category A drug2’3.
[041] Prior art product containing doxylamine provides this sedative antihistamine at a higher dose of 25mg only. Therefore, the patient requires to cut the tablet in half to obtain a lower dose. The present invention, however, provides a lower dose of this antihistamine.
[042] Unlike other prior art, the present invention provides compositions with both short and long- acting antihistamines. Compositions of the present invention comprising long-acting antihistamines like promethazine are useful when sedation for 8 hrs or more is desired, whereas a composition comprising dexchlorpheniramine or other short-acting antihistamines is helpful when sedation for more than 6 hrs is to avoid.
[043] Even after several decades since the Debendox was withdrawn from the Australian market, there is no product in Australia with similar composition, and Australian women are being denied safe and effective treatment for NVP4,5.
[044] Products containing sedative antihistamine as a single ingredient are not always the treatment option for all patient following their accessibility issues and concerns over adverse effects.
[045] The present invention alleviates the need for caffeine which is included in a prior art (Travacalm original ) to counterbalance the sedative effect of sedative antihistamine. The present invention achieves this objective by not solely relying on sedative antihistamine to provide the antiemetic effect. Instead, the present invention provides compositions, kits, and methods comprising one or more (activated and/or one or more inactivated) forms of vitamin B6 and ginger (in standardised and/or non-standardised forms) to achieve the anti-emetic effect.
VITAMIN B6
[046] NV is one of the symptoms of deficiency of vitamin B6. Vitamin B6 plays a vital role in the nervous system, metabolism pathways of NV. The body does not store vitamin B6, so people need to get from their daily diets6. Pyridoxal 5 ’-phosphate, pyridoxine 5’ phosphate, and pyridoxamine 5’ phosphate are activated forms of vitamin B6 ; and are also known as P5P or PLP, PNP, PMP, respectively. The conversion process from the inactive to the active form of vitamin B6 is enzyme- dependent ’ . Following the prevalence of relevant enzyme deficiencies, this conversion process does not occur the same way in all individuals. During pregnancy, because of hormonal changes and foetus demand, the level of vitamin B6 reduces. Activated and inactivated forms of vitamin B6 levels are
affected in patients with impaired liver functions10. Activated vitamin B6 levels are lower in a patient with Methylenetetrahydrofolate reductase (MTHFR) gene deficiency
[047] An activated and inactivated form of vitamin B6 may be a more efficient therapy for morning sickness . Addressing underlying deficiency of vitamin B6 would result in better outcome compared to only managing the symptoms of NV using pyridoxine hydrochloride (an inactivated form of vitamin B6) and/or sedative antihistamine and/or 5H3 receptor antagonist comprised in other prior art products which do not contain an activated form of vitamin B6. Research suggests that the activated form of vitamin B6 is better anti-emetic than the inactive form of vitamin B6 for the management of NV14. The present invention provides compositions, kits, and method that addresses this underlying cause better than other prior art (Elevit Morning Sickness Relief®’Pyridox®) products.
[048] There is no product with an approved indication comprising an activated form of vitamin B6 for the prevention, treatment, or management of NV. The present invention provides compositions, kits, and methods that make the activated form of vitamin B6 readily available. Hence it is more helpful for the prevention, treatment, and management of NV.
GINGER
[049] The chemical constituents of ginger vary significantly with species and geographical source15 . Also, all constituents of ginger do not have identical biological and physiological properties16,17. Ginger is dried using different drying methods, and the chosen method impacts the constituents of the product at the end . The anti-emetic properties of ginger are mainly due to active constituents from groups called ‘gingerols’ and ‘shogaols’ 19. Hence the therapeutic effect of all products containing ginger in non-standardised forms cannot be assumed the same.
[050] Several prior art (Travacalm original®) products contain such ‘non-standardised forms of ginger. However, there is no commercial product in Australia containing ginger in standardised forms.
[051] Volume after the extraction of gingerols and shogaols required to achieve the anti -emetic effect is much lesser than the volume of raw ginger powder containing the same amount of gingerols and shogaols. The present invention provides compositions comprising gingerols and shogaols in standardised forms, thereby provide unit doses with smaller volume, which would be hard to administer otherwise.
[052] The present invention provides scientifically identified anti-emetic ingredients of ginger in therapeutic doses. Compositions comprising such ingredients are more likely to be accepted and recommended by health care practitioners compared to ‘raw’ ginger present in prior art products.
GUIDELINES/PRODUCT LABELLING ISSUES
[053] Inconsistencies persist between guidelines accessed by GP, hospital doctors and, interpretation of the approved Indications and warnings on packaging, for management of NV by pharmacists. In Australia, pharmacists are hesitant to supply scheduled OTC products containing ingredients with anti-nausea or anti-emetic properties because these OTC products are not approved for the management or treatment of nausea or vomiting .
HEALTHCARE COST
[054] Cost for the government to avail the treatment for NV increases when patients are required to attend Medicare subsidised appointments to see doctors. Often such appointments are just needed to obtain prescriptions for anti-emetic medications because of scheduling of anti-emetics and/or to avail ‘off label’ use of OTC anti-emetic treatment options. This situation makes it hard to access anti-emetic products and increases avoidable use of healthcare resources that could have been diverted to manage more complex medical conditions of the population.
[055] The present invention also provides compositions, kits, and methods without scheduled ingredients. These embodiments achieve anti-nausea and anti-emetic effects via constituents of ginger (in standardised and/or in non-standardised forms) and vitamin B6 (activated and/or inactivated forms) only. By providing compositions, kits, and methods comprising ginger (standardised and/or non-standardised forms) and vitamin B6 (activated and/or inactivated forms) only, the present invention makes anti-emetic treatment options more accessible (without the intervention of a pharmacist or a doctor) to patients. Hence, it also reduces the health care cost of the government.
[056] Schedule 4 treatment options such as 5HT3 antagonists are expensive and subsidised by Pharmaceutical Benefits Scheme (PBS) only for the management of AINV. For example, cost to the patient for 10 tabs of 8 mg Ondansetron is $32.1921, the cheapest 5HT3 antagonist available under
PBS.
COMBINATIONS
[057] NV involves multiple pathophysiological mechanisms. Unlike other prior art products listed above, the present invention comprises multiple anti-emetic ingredients to provide additive and/or synergistic effects by acting on more than one pathophysiological mechanism.
[058] Unlike prior art compositions, the present invention provides compositions comprising standardised ginger and sedative antihistamines that target receptors present in both the CNS and gut.
[059] Some people do not endorse and/or suggest using anything that is not ‘organic’ and/or ‘natural’. The present invention also provides compositions comprising one or more activated forms and/or one or more inactivated forms of vitamin B6 and/or ginger in standardised or in nonstandardised forms, which would suit better to such population.
[060] In Australia, there is no commercial product available for the prevention, treatment and management of NV comprising:
(A) ginger in standardised forms with or without ginger in non-standardised forms.
(B) Doxylamine in less than 25mg with or without approved treatment indication for NV.
(C) (i) one or more activated forms of vitamin B6 with or without one or more inactivated forms of vitamin B6 and, (ii) ginger in non-standardised forms and/or ginger in standardised forms.
(D) (i) one or more activated forms of vitamin B6 and/or one or more inactivated forms of vitamin B6 and, (ii) one or two sedative antihistamines.
(E) (i) ginger in non-standardised forms and/or ginger in standardised forms and, (ii) one or two sedative antihistamines.
(F) (i) one or more activated forms of vitamin B6 and/or one or more inactivated forms of vitamin B6 and, (ii) ginger in non-standardised forms and/or ginger in standardised forms, (ii) one or two sedative antihistamines.
(G) (i) one or more inactivated forms of vitamin B6 and, (ii) ginger in standardised forms with or without ginger in non-standardised forms.
[061] Uncomplicated NV does not always require attention from the doctor. Uncomplicated but uncontrolled NV leads to hospitalisations which increases the use of healthcare resources. Regardless of the underlying cause, NV increases socioeconomic cost and reduces the productivity of patient. A study concluded that the NVP often remains untreated or undertreated. The present
invention provides choices of anti-emetic compositions, kits, and methods to suit various patient populations.
[062] There was need to develop novel pharmaceutical compositions, kits, and methods comprising multiple ingredients to avoid adverse effects of one ingredient that would occur when a higher dose of one anti-emetic ingredient is administered to achieve the higher anti-emetic effect. The present invention addresses this need by including multiple ingredients.
[063] The present invention has the advantage of providing flexibility to a subject experiencing NV to have a composition that treats NV at a time when a sedative or calmative effect is not required or to be avoided. For example, during work hours, when operating a machine or when attending to dependents, but also provides a composition that treats NV that further includes a sedative or calmative for assisting the subject to relax or fall asleep.
SUMMARY OF INVENTION
[064] The objective of the present invention is to achieve anti-nausea and anti-emetic effects via the actions of comprised ingredients on multiple pathophysiological mechanisms. The present invention provides compositions, kits, and methods that deliver anti-nausea and anti-emetic effects from at least two of the pharmacological approaches below: a. Suppressing receptors in the gastrointestinal tract, b. Suppressing receptors in the central nervous system (CNS), c. Reduction in oxidative stress (antioxidant properties), d. Addressing underlying vitamin B6 deficiency.
[065] Core ingredients of the present invention provide anti-nausea and anti-emetic properties by working on the same or different aspect of the pathophysiology of nausea and vomiting. Core ingredients of the present invention are; a. inactivated form(s) of vitamin B6, b. activated form(s) of vitamin B6, c. ginger in non-standardised forms, d. ginger in standardised form(s), e. sedative antihistamine(s).
[066] Vitamin B6 delivers anti-nausea and anti-emetic effect by reducing oxidative stress and 22 23 24 addressing underlying vitamin B6 deficiency ’ ’ . Vitamin B6 is one of the most central molecules in cellular metabolism. Nausea and/or vomiting can be a symptom of vitamin B6 deficiency because of various underlying reasons at the cellular level. Role of vitamin B6 extends to several metabolism processes.
[067] Vitamin B6 levels are reduced during the pregnancy, and hence vitamin B6 is helpful to
25 26 27 manage the NVP . Vitamin B6 is useful treatment option in other forms of nausea too. ’
[068] Amino acids are the building blocks of protein. Active co-enzyme or phosphorylated or also referred herein as the activated form of vitamin B6 plays the crucial role in the biosynthesis and degradation of amino acids. Neurotransmitters are required for communication in-between nerve cells and between nerve cells and other cells. Synthesis of these neurotransmitters requires enzymes. These enzymes use vitamin B6 as co-enzymes.
[069] Activation of vitamin B6 from an inactivated form is enzyme dependent. Considering the underlying cause of nausea, for some patients activated form of vitamin B6 could be more useful than the inactivated form of vitamin B6 or vice versa. The present invention provides compositions comprising one or more activated forms of vitamin B6 with or without one or more inactivated forms of vitamin B6.
[070] Pyridoxal 5'-phosphate (P5P) increases antioxidant enzyme activities in post-surgery patients . P5P breaks down homocysteine and hence helps to improve nausea related to PCOS. Vitamin B6 plays positive role in glutathione reductase dependent antioxidant system and provides defence against free radicals . Alcohol consumption increases oxidative stress and is primary cause of nausea related to alcohol use. Oxidative stress contributes to inflammation of GI tract during gastroenteritis. Hence managing inflammation would help to manage nausea related to gastroenteritis.
[071] Ginger delivers anti-nausea and anti-emetic effect by suppressing receptors in the gastrointestinal tract and in the central nervous system (CNS) , and by reducing oxidative stress.
[072] The present invention delivers embodiments comprising ginger as in standardised and nonstandardised forms. Pharmacological actions in both the forms of ginger are from the constituents of ginger. Some constituents of ginger act on receptors in GI tract whereas some on the receptors of the CNS . Considering the cost and underlying cause of nausea, ginger in standardised forms may be more suitable than non-standardised forms or vice versa.
[073] Anti-cancer treatments triggers chemoreceptor trigger zones and results in higher expression of 5HT receptors3**. Hence antagonism of 5-HT receptors results in anti-nausea and anti-emetic effects. Research indicates that constituents of ginger have 5HT3 antagonistic activity . Constituents of ginger with smaller molecular weight such as 6-gingerol, 8-gingerol and 6-shogaol can penetrate the blood brain barrier36.
[074] In addition, the ginger (and its constituents) acts peripherally, within the gastrointestinal tract, by increasing the gastric tone and motility due to anticholinergic and anti-serotonergic actions mainly due to action on serotonin (5-hydroxytryptamine, 5-HT3, and 5-HT4) and cholinergic (M3) receptor activities.
[075] Gingerol also has powerful anti-inflammatory and antioxidant effects and may help to reduce oxidative stress, which results from an excessive amount of free radicals in the body. Gingerols and shogaols have higher antioxidant properties .
[076] Sedative antihistamines deliver anti-nausea and anti-emetic effects via suppression of Hl receptors in the CNS and gut. Sedative antihistamines can also cross the blood brain barrier (BBB). Sedative antihistamines’ anti-nausea and anti-emetic effects are from their actions on receptors of vomiting centre after crossing the blood brain barrier, receptors of CTZ (also known as area postrema or AP) without crossing the BBB and receptors of the gut. Some sedative antihistamines have anticholinergic properties and ability to block muscarinic receptors in the CNS and gut. The sedating antihistamines also have a calmative, relaxant, and muscle relaxant properties.
[077] The sedating antihistamines used herein have an anti-emetic effect and are particularly useful for treating nausea and vomiting related to pregnancy, drugs induced, alcohol induced, motion sickness, gastroenteritis, PCOS, anti-cancer treatment and surgery.38’39’40’41’42'
[078] CTZ, also known as area postrema (AP) is located outside the blood brain barrier, within the dorsal surface of medulla oblongata, on the floor of the fourth ventricle of the brain. Emetic agents in the blood are detected by the receptors present in the CTZ which induces vomiting. The present invention provides compositions with ingredients that acts on receptors of CNS including receptors of CTZ (without crossing the BBB), receptors of vomiting centre (after crossing the BBB).
[079] Chemoreceptor trigger zone (CTZ) contains dopamine (D2), serotonin (5-HT3), muscarinic (Ml), histamine (Hl), opioid and NK1 receptors. Vestibular centre contains histamine (Hl) and muscarinic (Ml) receptors, serotonin (5-HT3), dopamine (D2) and NK1 receptors. Vomiting centre
contain serotonin (5-HT3) and muscarinic (Ml) receptors. GI track nerves (and other periphery nerves) contains serotonin (5-HT3), dopamine (D2) and NK1 receptor.
[080] The present invention delivers synergistic and/or additive anti-nausea and anti-emetic effects by combining Hl receptor antagonists (sedative antihistamines), muscarinic receptor antagonists (promethazine, doxylamine, diphenhydramine, dimenhydrinate, (6)-gingerol, (8)-gingerol, (10)- gingerol, and (6)-shogaol), dopamine receptor antagonists (promethazine, dimenhydrinate), cholinergic receptor antagonists (promethazine, cyclizine, dexchlorpheniramine, dimenhydrinate), 5-HT antagonists (promethazine, (6)-gingerol, (8)-gingerol, (lO)-gingerol, and (6)-shogaol), Neurokinin 1 (NK1) antagonists ((6)-gingerol, (8)-gingerol, (lO)-gingerol, and (6)-shogaol), and antioxidants (activated and inactivated B6, gingerols, shogaols, paradols).
[081] In an aspect, the present invention relates to a pharmaceutical composition for the prevention, treatment, and management of nausea, vomiting, or combination thereof, comprising:
(a) a ginger extract containing gingerols, shogaols, paradols, or combination thereof,
(b) pyridoxal 5 ’-phosphate,
(c) one or more sedative antihistamine(s), and
(d) excipients required to prepare the pharmaceutical composition.
[082] In another aspect of the present invention, the gingerols, shogaols, paradols, or combination thereof present in an amount in the range of 0.5mg to 300mg, the pyridoxal 5 ’-phosphate is present in an amount in a range of Img to 200mg, and the one or more sedative antihistamine(s) is present in an amount in a range of 0.5mg to 200mg.
[083] In another aspect of the present invention, the gingerol is selected from the group consisting of (6)-gingerol, (8)-gingerol, (lO)-gingerol, (6)-gingerdione, (6)-gingerdiol, (6)-gingerdiol diacetate, (6)-ginger sulphonic acid, 6)-demethoxygingerol, (6)-methylgingerol, or combination thereof; the paradol is (6)-paradol, (8)-paradol, (lO)-paradol, or combination thereof; and the shogaol is (6)- demethoxyshogaol, (6)-shogaol, (8)-shogaol, (10) shogaol, (6)-methylshogaol, (6)-hydroxyshogaol, (6)-dehydroshogaol, or combination thereof and one or more pharmaceutically acceptable salt(s), metabolite(s), analog(s), polymorph(s), isomer(s), prodrug(s), solvate(s), hydrate(s), or derivative(s) thereof.
[084] In another aspect of the present invention, the pharmaceutical composition further comprises pyridoxal, pyridoxamine, pyridoxine 5' phosphate and pyridoxamine 5' phosphate.
[085] In another aspect of the present invention, the one or more sedative antihistamine is shortacting, long-acting, intermediate-acting, or combination thereof.
[086] In another aspect of the present invention, the one or more sedative antihistamine is selected from the group consisting of doxylamine and salt thereof, dexchlorpheniramine and salt thereof, diphenhydramine and salt thereof, dimenhydrinate and salt thereof, chlorpheniramine and salt thereof, brompheniramine and salt thereof, pheniramine and salt thereof, hydroxyzine and salt thereof, cyproheptadine and salt thereof, carbinoxamine and salt thereof, pyrilamine and salt thereof, tripelennamine and salt thereof, phenindamine and salt thereof, trimeprazine, and salt thereof, cyclizine and salt thereof, promethazine and salt thereof, phenyltoloxamine and salt thereof, cyproheptadine and salt thereof, alimemazine and salt thereof, clemastine and salt thereof, ketotifen and salt thereof, mepyramine and salt thereof, antazoline and salt thereof, orphenadrine and salt thereof, bromazine and salt thereof, dexbrompheniramine and salt thereof, tripolidine and salt thereof, chlorcyclizine and salt thereof, hydroxyzine and salt thereof, meclizine and salt thereof, and azatadine and salt thereof.
[087] In another aspect of the present invention the salt is selected from the group consisting of succinate, maleate, esters, amines, hydrochloride, phosphate, calcium phosphate, or dihydrochloride.
[088] In another aspect, the present invention relates to a pharmaceutical composition for the prevention, treatment, and management of nausea, vomiting, or combination thereof comprising of:
(a) a ginger extract containing gingerols, shogaols, paradols, or combination thereof,
(b) pyridoxal 5’-phosphate, pyridoxal, pyridoxamine, pyridoxine 5' phosphate and pyridoxamine 5' phosphate, or combination thereof,
(c) one or more sedative antihistamine(s),
(d) (i) pyridoxine hydrochloride as an inactivated form of vitamin B6, (ii) a non-standardised form of ginger, (iii) Levomepromazine, or combination thereof and
(e) excipients required to prepare a pharmaceutical composition.
[089] In another aspect of the present invention, the composition further comprises other ingredients such as caffeine, antioxidants (e.g. glutathione, reduced glutathione), one or more forms of iron, vitamin A (e.g., retinol acetate), one or more forms of vitamin B12, vitamin B3, alpha-lipoic acid (R or S form), one or more forms of vitamin C, alpha tocotrienol, coenzyme Q10 (activated or inactivated), ubiquinol, zinc, selenium, magnesium citrate, magnesium glycinate, and magnesium
chelates, Hl antagonists; H2 antagonists; proton-pump inhibitors, analgesics (paracetamol); flavin mononucleotide (FMN, also known as riboflavin-5-phosphate or R5P), metabolites of riboflavin; folinic acid; 5-MTHF; folic acid; probiotics; or combination thereof.
[090] In another aspect of the present invention, lactose, gluten or dairy-derived excipients are excluded.
[091] In another aspect of the present invention, one, more or all pharmaceutical composition(s) are modified to release the ingredients at a specific location of the body and/or at a specific rate and/or for a specific time duration.
[092] In yet another aspect, the present invention relates to kit for the prevention, treatment, and management of nausea, vomiting, or combination thereof comprising:
(i) a first pharmaceutical composition as claimed in any one of the claims 1 to 11 provided that the first composition is with one or more sedative antihistamine(s); and
(ii) a second pharmaceutical composition as claimed in any one of the claims 1 to 11 provided that the second composition is without one or more sedative antihistamine(s) or in an amount that is less likely to cause the sedation; wherein the kit is adapted to allow access to each pharmaceutical composition at the same or different times.
[093] In another aspect of the present invention, the kit is designed or presented with the indicia distinguishing the first and second pharmaceutical composition from each other, dosage instructions for a specific medical condition, instructions for coordinating the administration of each pharmaceutical composition wherein;
(i) the first pharmaceutical composition is to administer during a particular time and/or at specific time interval(s) of the day or over 24 hrs period or an event, when sedation or sleep is desirable or not contraindicated, or
(ii) the first or second pharmaceutical composition is to administer during a particular time and/or at specific time interval(s) of the day or over 24 hrs period or an event, when sedation or sleep is not desirable or not expected or contraindicated, wherein the container that incorporates the kit includes the indicia, the instructions, and a plurality of first and second pharmaceutical compositions, wherein the kit is designed for ‘day and night’ use and/or is presented as a kit comprising ‘drowsy’ and/or ‘non-drowsy’ pharmaceutical compositions,
wherein the first pharmaceutical composition is administered with or without the second pharmaceutical composition, and wherein the kit is designed or presented to provide access to each pharmaceutical composition, the indicia distinguishing each pharmaceutical composition from each other, dosage instructions related to a specific medical condition, instructions for coordinating the administration of each pharmaceutical composition for the duration of one to four weeks or a month.
[094] In another aspect of the present invention, each pharmaceutical composition present therein comprises a different sedative antihistamine and/or dose of each sedative antihistamine is different in each pharmaceutical composition present therein.
[095] In another aspect of the present invention, the pharmaceutical composition or kit is prepared in a compounding pharmacy or in a facility approved by the relevant authority of the local jurisdiction to manufacture therapeutic preparation.
[096] In yet another aspect, the present invention relates to a method of prevention, treatment, and management of nausea, vomiting or combination thereof comprising administering the therapeutically effective amount of the pharmaceutical composition and kit as claimed in claims 1 to 15 to a subject in need thereof.
[097] In yet another aspect, the present invention relates to a pharmaceutical composition and kit for use in the manufacture of medicament for the prevention, treatment, and management of nausea, vomiting or combination thereof.
[098] In yet another aspect, the present invention relates to a use of the pharmaceutical composition for the prevention, treatment, and management of nausea, vomiting or combination thereof.
DETAILED DESCRIPTION OF THE INVENTION
[099] The present invention provides compositions, kits and methods comprising one or more of the core ingredients to achieve the objective described herein.
[0100] It will be understood that the present invention disclosed and defined in this specification extends to all alternative combinations derived from achieving the objectives of the present invention described herein or evident herein. All these different combinations constitute various alternative aspects of the present invention.
[0101] One skilled in the art will recognise many methods and materials similar or equivalent to those described herein, which may be used in the practice of the present invention. The present invention is in no way limited to the methods and materials described in this invention.
[0102] The term ‘comprising’, which is synonymous with ‘including’ ‘containing’, or ‘characterised by’ here, is defined as being inclusive or open-ended and does not exclude additional, unrecited elements or method steps, additives, components, integers, or steps.
[0103] For purposes of interpreting this specification, terms used in the singular will also include the plural and vice versa.
[0104] Further aspects of the present invention and further embodiments of the aspects described in the preceding paragraphs will become apparent from the following description, given by way of example. [0105] Reference will now be made in detail to some embodiments of the present invention. While the present invention will be described in conjunction with the embodiments, it will be understood that the intention is not to limit the present invention to any embodiments. On the contrary, the present invention is intended to cover all alternatives, modifications, and equivalents, which may be included within the scope of the present invention as defined by the claims. Skilled artisans will recognise that the examples provided herein have many useful alternatives that fall within the scope of the present invention.
[0106] Compositions, kits and methods of the present invention comprises;
(A) ginger in standardised forms with or without ginger in non-standardised forms.
(B) (i) one or more activated forms of vitamin B6 with or without one or more inactivated forms of vitamin B6 and, (ii) ginger in non-standardised forms and/or ginger in standardised forms.
(C) (i) one or more activated forms of vitamin B6 and/or one or more inactivated forms of vitamin B6 and, (ii) one or two sedative antihistamines.
(D) (i) ginger in non-standardised forms and/or ginger in standardised forms and, (ii) one or two sedative antihistamines.
(E) (i) one or more activated forms of vitamin B6 and/or one or more inactivated forms of vitamin B6 and, (ii) ginger in non-standardised forms and/or ginger in standardised forms, (ii) one or two sedative antihistamines.
(F) (i) one or more inactivated forms of vitamin B6 and, (ii) ginger in standardised forms with or without ginger in non-standardised forms.
[0107] In an embodiment, the present invention relates to a pharmaceutical composition for the prevention, treatment, and management of nausea, vomiting or combination thereof comprising of:
(a) a ginger extract containing gingerols, shogaols, paradols, or combination thereof,
(b) pyridoxal 5 ’-phosphate,
(c) one or more sedative antihistamine(s), and
(d) excipients required to prepare the pharmaceutical composition.
[0108] In an embodiment, the present invention relates to a pharmaceutical composition for the prevention, treatment, and management of nausea, vomiting or combination thereof comprising of:
(a) a ginger extract containing gingerols, shogaols, paradols, or combination thereof,
(b) pyridoxal 5’-phosphate, pyridoxal, pyridoxamine, pyridoxine 5' phosphate and pyridoxamine 5' phosphate, or combination thereof
(c) one or more sedative antihistamine(s), and
(d) excipients required to prepare the pharmaceutical composition.
[0109] In another embodiment, the present invention relates to relates to a pharmaceutical composition for the prevention, treatment, and management of nausea, vomiting or combination thereof comprising of:
(a) a ginger extract containing gingerols, shogaols, paradols or combination thereof,
(b) pyridoxal 5 ’-phosphate pyridoxal, pyridoxamine, pyridoxine 5' phosphate and pyridoxamine 5' phosphate, or combination thereof,
(c) one or more sedative antihistamine(s),
(d) (i) pyridoxine hydrochloride as an inactivated form of vitamin B6, (ii) a non-standardised form of ginger, (iii) Levomepromazine, or combination thereof and
(e) excipients required to prepare a pharmaceutical composition. In the present invention, activated form(s) of vitamin B6 is selected from the group consisting of pyridoxal 5 ’-phosphate, pyridoxine 5' phosphate and pyridoxamine 5' phosphate; also known as P5P or PLP, PNP, PMP respectively, and/or one or more pharmaceutically acceptable salt(s), metabolite(s), analog(s), polymorph(s), isomer(s), prodrug(s), solvate(s), hydrate(s), or derivative(s) thereof. Preferably, an activated form of B6 is PLP (also referred as pyridoxal 5’-phosphate, P5P).
[0110] In the present invention, inactivated form(s) of vitamin B6 is selected from the group consisting of pyridoxine and/or salts thereof, pyridoxal and/or salts thereof, pyridoxamine and/or salts thereof, also known as PYN, PYL, PYM respectively, and/or one or more pharmaceutically acceptable salt(s),
metabolite(s), analog(s), polymorph(s), isomer(s), prodrug(s), solvate(s), hydrate(s), or derivative(s) thereof. Preferably, an inactivated form of B6 is pyridoxine hydrochloride (pyridoxine HCL).
[0111] In the present invention, activated and inactivated forms of vitamin B6 may be presented in any combination, such as but not limited to, PNP+PMP, PNP+PLP, PMP+PLP, PMP+PNP+PLP, PYL+PNP+PMP, PYM+PNP+PMP, PYL+PNP+PLP, PYM+PNP+PLP, PYL+PMP+PLP, PYM+PMP+PLP, PMP+PNP+PLP+PYL, PYM+PMP+PNP+PLP etc, or salt(s) thereof. Preferably, the combination of activated and inactivated forms is pyridoxal 5 ’-phosphate and pyridoxine HCL.
[0112] In any aspect of the invention described herein, one or more pharmaceutically acceptable salts including for example and without limitation; esters, amines, hydrochloride, phosphate, calcium phosphate, or dihydrochloride of pyridoxine, pyridoxal, and pyridoxamine.
[0113] In the present invention, ginger in non-standardised forms can be powder, extract or any other form of mixture that is derived from one or more parts of the ginger plant, including, but not limited to leaves, root, rhizome, or stems, either from the same or different species from the family of Zingiberaceae, cultivated in any region of the world.
[0114] Standardisation of ginger herein means the process of establishing a set of quantitative parameters for the chemical compositions to ensure quantitative values for the assurance of definitive qualitative and quantitative values to achieve efficacy, safety and reproducibility. Furthermore, because constituents of ginger have different biological properties, the present invention, considering the indication and desired pharmacological action, comprises constituents of ginger in standardised form(s) to ensure the minimum quantity of specific constituents and/or constituents from one or more 'chemical groups'.
[0115] Herein, standardisation by chemical group(s) means quantitative standardisation for the constituents that share the same chemical group(s). For example, quantitative standardisation of constituents from the gingerols and/or shogaols group(s) to ensure that an embodiment contains at least a specific amount of chemical constituents from a ‘gingerols’ and/or ‘shogaols’ and/or ‘paradols’ group(s). Embodiments may be standardised for only one group of constituents, i.e., standardisation for only ‘gingerols’ group of constituents, standardisation of only ‘shogaols’ group of constituents, standardisation of only ‘paradols’ group of constituents.
[0116] Embodiments may be standardised for one or more individual constituents, i.e., standardisation for only (6)-gingerol, standardisation for the total quantity of (6)-gingerols and (6)-shogaols, standardisation for only (6)-gingerol, standardisation for the total quantity of (6)-gingerol, (8)-gingerol
and (lO)-gingerol, standardisation for only (6)-shogaol, standardisation for the total quantity of (6)- shogaol, (8)-shogaol and (lO)-shogaol.
[0117] Embodiments may be standardised for one constituent and 'chemical group(s)' i.e., standardisation for (6)-gingerol and shogaols.
[0118] In the present invention, ginger in standardised form is a mixture of constituents present in ginger, and these constituents are selected from the group consists of, including, but not limited to, (6)- gingerol, (8)-gingerol, (lO)-gingerol, (6)-gingerdione, (6)-gingerdiol, (6)-gingerdiol diacetate, (6)- ginger sulphonic acid, (6)-paradol, (8)- paradol, (lO)-paradol, (6)-demethoxygingerol, (6)- methylgingerol, (6)-demethoxyshogaol, (6)-shogaol, (8)-shogaol, (10) shogaol, (6)-methylshogaol, (6)- hydroxyshogaol, (6)-dehydroshogaol, 2-propyl-5(-(3-methoxy-4- hydroxyphenyl)ethyl)-furan, curcuminoids, hexahydrocurcumin, demethylatedhexahydrocurcumin, demethoxylatedhexahydrocurcumin, methoxylatedhexahydrocurcumin, methoxylatedgingerenone a, demethoxylatedgingerenone a, P-bisabolene, a-curcumene, zingiberene, a-farnesene, and P- sesquiphellandrene, quercetin, zingerone, gingerenone-a, and 6-dehydrogingerdione, P-bisabolene, a- curcumene, zingiberene, a-farnesene, and P-sesquiphellandrene and/or one or more pharmaceutically acceptable salt(s), metabolite(s), analog(s), polymorph(s), isomer(s), prodrug(s), solvate(s), hydrate(s), or derivative(s) thereof. Preferably, standardised forms of ginger constituents are (6)-gingerol, (8)- gingerol, (lO)-gingerol, (6)-shogaol, (8)-shogaol, (10) shogaol, (6)-paradol, (8)- paradol, (lO)-paradol, or more pharmaceutically acceptable salt(s), metabolite(s), analog(s), polymorph(s), isomer(s), prodrug(s), solvate(s), hydrate(s), or derivative(s) thereof.
[0119] In the present invention, standardised forms of ginger are standardised for one or more groups of constituents of the ginger such as, including but not limited to gingerols, shogaols, hexahydrocurcumin, and its derivatives (curcuminoids), zingerones, gingerenones, gingerdiones, gingerdiols, paradols, gingeroneA, diarylheptanoids. Preferably, standardised forms of ginger are standardised by gingerols, shogaols, paradols groups of constituents.
[0120] In the present invention, one or more sedative antihistamines are selected from the group consisting of doxylamine and salt thereof, dexchlorpheniramine and salt thereof, diphenhydramine and salt thereof, dimenhydrinate and salt thereof, chlorpheniramine and salt thereof, brompheniramine and salt thereof, pheniramine and salt thereof, hydroxyzine and salt thereof, cyproheptadine and salt thereof, carbinoxamine and salt thereof, pyrilamine and salt thereof, tripelennamine and salt thereof, phenindamine and salt thereof, trimeprazine, and salt thereof, cyclizine and salt thereof, promethazine
and salt thereof, phenyltoloxamine and salt thereof, cyproheptadine and salt thereof, alimemazine and salt thereof, clemastine and salt thereof, ketotifen and salt thereof, mepyramine and salt thereof, antazoline and salt thereof, orphenadrine and salt thereof, bromazine and salt thereof, dexbrompheniramine and salt thereof, tripolidine and salt thereof, chlorcyclizine and salt thereof, hydroxyzine and salt thereof, meclizine and salt thereof, and azatadine and salt thereof, levomepromazine and salt thereof. Preferably, doxylamine and salt thereof, promethazine and salt thereof, diphenhydramine and salt thereof, dimenhydrinate and salt thereof, dimenhydrinate and salt thereof, and dimenhydrinate and salt thereof, and levomepromazine and salt thereof.
[0121] In an embodiment of the present invention, the one or more sedative antihistamine is present in an amount in a range of 0.5mg to 200mg per unit dose.
[0122] In an embodiment of the present invention, the gingerols, shogaols, paradols or combination thereof present in an amount in the range of 0.5mg to 300mg per unit dose.
[0123] In an embodiment of the present invention, Pyridoxal 5 ’ -phosphate is present in an amount in a range of Img to 200mg.
[0124] Examples of the present inventions are listed below. However, this invention extends to all possible combinations evident herein and recognised by the person skilled in the art.
• pyridoxal 5 ’-phosphate + ginger standardised by gingerols and/or shogaols
• pyridoxal 5 ’-phosphate + pyridoxine HCL+ ginger standardised by gingerols and shogaols
• pyridoxal 5 ’-phosphate + pyridoxine HCL+ non-standardised ginger
• pyridoxal 5 ’-phosphate + ginger standardised by gingerols and shogaols + doxylamine
• pyridoxal 5 ’-phosphate + pyridoxine HCL+ ginger standardised by gingerols and shogaols + doxylamine
• pyridoxal 5 ’-phosphate + pyridoxine HCL+ non-standardised ginger + doxylamine
• pyridoxal 5 ’-phosphate + ginger standardised by gingerols and shogaols + promethazine
• pyridoxal 5 ’-phosphate + pyridoxine HCL+ ginger standardised by gingerols and shogaols + promethazine
• pyridoxal 5 ’-phosphate + pyridoxine HCL+ non-standardised ginger + promethazine
• pyridoxal 5 ’-phosphate + ginger standardised by gingerols and shogaols + cyclizine
• pyridoxal 5 ’-phosphate + pyridoxine HCL+ ginger standardised by gingerols and shogaols + cyclizine
• pyridoxal 5 ’-phosphate + pyridoxine HCL+ non-standardised ginger + cyclizine
• pyridoxal 5 ’-phosphate + ginger standardised by gingerols and shogaols + levomepromazine
• pyridoxal 5 ’-phosphate + pyridoxine HCL+ ginger standardised by gingerols and shogaols + levomepromazine
• pyridoxal 5 ’-phosphate + pyridoxine HCL+ non-standardised ginger + levomepromazine
• pyridoxal 5 ’-phosphate + ginger standardised by gingerols and shogaols + dexchlorpheniramine
• pyridoxal 5 ’-phosphate + pyridoxine HCL+ ginger standardised by gingerols and shogaols + dexchlorpheniramine
• pyridoxal 5 ’-phosphate + pyridoxine HCL+ non-standardised ginger + dexchlorpheniramine
• pyridoxal 5 ’-phosphate + ginger standardised by gingerols and shogaols + dimenhydrinate
• pyridoxal 5 ’-phosphate + pyridoxine HCL+ ginger standardised by gingerols and shogaols + dimenhydrinate
• pyridoxal 5 ’-phosphate + pyridoxine HCL+ non-standardised ginger + dimenhydrinate
• pyridoxal 5 ’-phosphate + ginger standardised by gingerols and shogaols + diphenhydramine
• pyridoxal 5 ’-phosphate + pyridoxine HCL+ ginger standardised by gingerols and shogaols + diphenhydramine
• pyridoxal 5 ’-phosphate + pyridoxine HCL+ non-standardised ginger + diphenhydramine
• pyridoxal 5 ’-phosphate + pyridoxine HCL+ doxylamine
• pyridoxal 5 ’-phosphate + pyridoxine HCL+ promethazine
• pyridoxal 5 ’-phosphate + pyridoxine HCL+ dexchlorpheniramine
• pyridoxal 5 ’-phosphate + pyridoxine HCL+ levomepromazine
• pyridoxal 5 ’-phosphate + pyridoxine HCL+ dimenhydrinate
• pyridoxal 5 ’-phosphate + pyridoxine HCL+ diphenhydramine
• pyridoxal 5 ’-phosphate + pyridoxine HCL+ cyclizine
• ginger standardised by gingerols and shogaols + doxylamine
• ginger standardised by gingerols and shogaols + promethazine
• ginger standardised by gingerols and shogaols + dexchlorpheniramine
• ginger standardised by gingerols and shogaols + levomepromazine
• ginger standardised by gingerols and shogaols + dimenhydrinate
• ginger standardised by gingerols and shogaols + diphenhydramine
• ginger standardised by gingerols and shogaols + cyclizine
• non-standardised ginger + pyridoxal 5 ’-phosphate
• non-standardised ginger + doxylamine
• non-standardised ginger + promethazine
• non-standardised ginger + dexchlorpheniramine
• non-standardised ginger + levomepromazine
• non-standardised ginger + dimenhydrinate
• non-standardised ginger + diphenhydramine
• non-standardised ginger + cyclizine
• pyridoxal 5 ’-phosphate + non-standardised ginger + doxylamine
• pyridoxal 5 ’-phosphate + non-standardised ginger + promethazine
• pyridoxal 5 ’-phosphate + non-standardised ginger + dexchlorpheniramine
• pyridoxal 5 ’-phosphate + non-standardised ginger + levomepromazine
• pyridoxal 5 ’-phosphate + non-standardised ginger + dimenhydrinate
• pyridoxal 5 ’-phosphate + non-standardised ginger + diphenhydramine
• pyridoxal 5 ’-phosphate + non-standardised ginger + cyclizine
• Gingerol + Pyridoxal 5 Phosphate
• Shogaol + Pyridoxal 5 Phosphate
• Standardised Ginger ( Gingerol and/or Shogaol) + Pyridoxal 5 Phosphate
• Standardised Ginger (Gingerol and/or Shogaol) + Pyridoxal 5 Phosphate + Pyridoxine
• Standardised Ginger ( Gingerol and/or Shogaol) + Sedative Antihistamine
• Standardised Ginger (Gingerol and/or Shogaol) + Pyridoxal 5 Phosphate + Pyridoxine + Sedative Antihistamine
• Standardised Ginger ( Gingerol and/or Shogaol) + levomepromazine
• Standardised Ginger ( Gingerol and/or Shogaol) + Sedative Antihistamine + levomepromazine
• Standardised Ginger ( Gingerol and/or Shogaol) + Sedative Antihistamine and/or levomepromazine and/or Pyridoxal 5 Phosphate
• Gingerol + Pyridoxine + Doxylamine
• Pyridoxine 5 Phosphate + Pyridoxine + Dexchlorpheniramine -Day and night version
• Standardised Ginger (Gingerol and/or Shogaol) + Pyridoxine
[0125] Embodiments may include any short-acting antihistamine combined with a long-acting antihistamine.
[0126] Caffeine may be present in any aspect of the present invention to treat NV to counterbalance the sedation effect of one or more antihistamines.
[0127] Embodiments may include other antioxidants, including but not limited to, glutathione, reduced glutathione, vitamin A (e.g., retinol acetate), one or more forms of vitamin B12, vitamin B3, alpha-lipoic acid (R and/or S form), one or more forms of iron, one or more forms of vitamin C, alpha tocotrienol, coenzyme Q10 (activated or inactivated), ubiquinol, zinc, selenium, magnesium citrate, magnesium glycinate, and magnesium chelates or any other forms thereof.
[0128] Flavin mononucleotide (FMN, also known as riboflavin-5-phosphate or R5P), a riboflavin metabolite, may be present in any aspect of the present invention described herein to improve the bioavailability of pyridoxal5'-phosphate (PLP) to achieve the same objective.
[0129] Embodiments described herein may be given with FMN, folinic acid, 5-MTHF, and folic acid either in a single unit or separate unit doses.
[0130] Embodiments may include probiotics with or without prebiotic to achieve the same objective.
[0131] The ‘active ingredients’ or ‘core ingredients’ used in the present invention can be used as pharmaceutically acceptable salt(s), metabolite(s), analog(s), polymorph(s), isomer(s), prodrug(s), solvate(s), hydrate(s), or derivative(s) thereof.
[0132] The invention provides kits and methods for prevention, treatment and management of nausea and vomiting comprising one or more dosage units each comprising one or more of:
(i) inactivated form(s) of vitamin B6,
(ii) activated form(s) of vitamin B6,
(iii) ginger in non-standardised forms,
(iv) ginger in standardised form(s),
(v) sedative antihistamine(s); indicia distinguishing all comprised dosage units from each other; indicia distinguishing sedative dosage units causing sedation from the non-sedative dosage units; indicia distinguishing sedative dosage units for administration during a particular time of the day or event when sedation or sleep is desirable or not contraindicated; indicia distinguishing non-sedative dosage units for administration during a particular time of the day or event when sedation or sleep is not desirable or contraindicated;
wherein instructions are provided for coordinating the administration of each dosage unit as a treatment regimen whereby a dosage unit is for administration during a particular time of the day or event; wherein a container or packaging that incorporates the indicia, the instructions and a plurality of each dosage units; wherein a blister card individually and releasably containing the unit doses; wherein said dosage units are arranged horizontally or vertically in order of their use across the blister card.
Preferably, the invention provides kits for promoting the proper sequential oral administration of pharmaceutically active ingredients.
Such kits and methods may have one or all features described herein.
[0133] The skilled person will understand that active ingredients may be free form, in various salt forms, various hydration states, etc. If, for example, a different salt form of an active ingredient is used in the invention, the skilled person will understand that the amount will need to be adjusted in accordance with the molecular weight.
[0134] 'Unit dose' or 'unit dosage' herein is a dosage form comprising an amount of therapeutically active ingredients suitable for administration in one single dose.
[0135] The present invention provides compositions, kits and methods comprising active ingredients in a range of doses considering the severity of nausea and vomiting, medical conditions, age, and underlying cause.
[0136] The dose range of each ingredient is described herein. Herein above, the dose range is for a unit dose. The present invention is not limited to these dose ranges. The dose of the comprised ingredient can be less or more than the described herein to achieve desired anti-nausea and anti-emetic effects. a) Doxylamine may be present in any aspect of the invention described herein at an amount per unit dose of about 0.5mg to 200 mg. b) Diphenhydramine may be present in any aspect of the invention described herein at an amount per unit dose of about 0.5mg to 200 mg. c) Dimenhydrinate may be present in any aspect of the invention described herein at an amount per unit dose of about 0.5mg to 300mg. d) Promethazine may be present in any aspect of the invention described herein at an amount per unit dose of about 0.5mg to 200mg.
e) Cyclizine may be present in any aspect of the invention described herein at an amount per unit dose of about 0.5mg to 200mg. f) Levomepromazine may be present in any aspect of the invention described herein at an amount per unit dose of about 0.5mg to lOOmg. g) Dexchlorpheniramine may be present in any aspect of the invention described herein at an amount per unit dose of about 0.5mg to 25mg. h) Ginger in non-standardised forms may be present in any aspect of the invention described herein at an amount per unit dose of about 100 mg to 2000mg or equivalent thereby. i) Ginger extract in standardised forms may be present in any aspect of the invention described herein at an amount per unit dose of about 2mg to 2000mg. j) gingerols, shogaols, paradols, or combination thereof may be present in any aspect of the invention described herein at an amount per unit dose of about 0.5mg to 300 mg, k) Pyridoxine may be present in any aspect of the invention described herein at an amount per unit dose of about Img to 200mg. l) Pyridoxal 5 ’-phosphate may be present in any aspect of the invention described herein at an amount per unit dose of about Imgto 200mg.
[0137] Kits or methods can be designed using this unit dose ranges to achieve the same objective. The present invention extends to any compositions, kits and methods recognised by one skilled in the art to achieve the effective concentration of one or more comprised ingredients to treat NV.
[0138] As described herein, a compound or active agent or active ingredient or core ingredient is present in a composition or in combination, in an amount effective to provide the desired therapeutic or physiological effect or outcome. This effect may be the treatment, alleviation, diminishment, or amelioration of nausea and/or vomiting. Undesirable effects, e.g., side effects, are sometimes manifested along with the desired therapeutic effect; hence, a practitioner balances the potential benefits against the potential risks in determining an appropriate ‘effective amount’. The exact amount required will vary from subject to subject, depending on the species, age, medical condition, and general condition of the subject, mode of administration and the like. An appropriate ‘effective amount’ in any individual case may be determined using routine experimentation by one skilled in the art.
[0139] It will be understood that the specific dose level for any patient will depend upon a variety of factors, including the activity of the specific composition employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination (i.e., other drugs being used to treat the patient), and the severity of the particular disorder. However, over the counter formulations are typically provided to patients as fixed dose, for example, tablets. Therefore, patient dosage may be adjusted by adjusting the number of fixed doses, for example, by changing the number of tablets taken or by adjusting the timing for the next dose.
[0140] The present invention provides compositions, kits, and methods for preventing, treating, and managing NV related to pregnancy, drug use, alcohol use, motion sickness, gastroenteritis, PCOS, anti-cancer and surgery. Embodiments may be used to achieve any desired outcome, including but not limited to minimal reduction to complete elimination of nausea and/or vomiting any time prior, during or after episode of nausea and/or vomiting related to pregnancy, drug use, alcohol use, motion sickness, gastroenteritis, PCOS, anti-cancer and surgery. Embodiments may be used to design a kit or a method in combination with other anti-nausea and/or anti-emetic treatments. Depending on the objective and indication(s), which can be prevention, treatment or management, amount of the comprised ingredient may vary in embodiments. Embodiments may be used to design kits or methods combined with other pharmacological or non-pharmacological interventions to achieve the same objective.
[0141] Embodiments of the present invention may be administered by a patient, a healthcare professional or a carer in a hospital, home, or caring facility. Embodiments may be prepared in a community, hospital pharmacy, or facility approved by the relevant authority to manufacture therapeutic preparation for human or non-human use.
[0142] Regarding NVP, embodiments of the present invention may be used during the first, second or third trimester of the pregnancy to achieve the desired outcome, including but not limited to minimal reduction to complete elimination of nausea and/or vomiting for any particular time of the day, throughout the day or every day during the pregnancy.
Embodiments may be used as single or multiple dosage forms or to design a kit or a method to achieve the desired outcome for the pregnant woman. Embodiments may be used to design a kit, or a method combined with ingredients such as folinic acid, 5-MTHF, folic acid, multivitamins; or may be combined with any other anti-nausea or anti-emetic treatments.
[0143] Regarding drug use, embodiments may be designed in combination with analgesics, benzodiazepines, other anti-emetics, anti-psychotics, or naloxone for the NV related to drug use or overdose.
[0144] Regarding alcohol use, embodiments may be designed comprising core ingredients of the present invention combined with non-sedative antihistamines and/or antioxidants for the prevention, treatment, and management of nausea and/or vomiting and/or facial flushing and/or erythema and/or hangover associated with alcohol use or overdose.
[0145] Regarding motion sickness, embodiments of the present invention may be used prophylactically to prevent the occurrence of motion sickness. Prophylactic use of embodiments is preferably within 2 hrs, 15 to 30 minutes more preferred, before expected symptoms.
[0146] Regarding gastroenteritis, embodiments may be combined with anti-diarrhoeal, rehydration salts or antibiotics.
[0147] Regarding PCOS, kits and/or methods can be used on an ad-hoc basis or designed to meet a patient’s requirements on one or more particular day(s) of the menstrual cycle. Embodiments may be designed with coenzyme Q10 (activated or inactivated), ubiquinol, folinic acid, folic acid or 5-MTHF (methylfolate).
[0148] Regarding AINV, cancer herein meaning any form of abnormal growth of cells in a subject. Anti-cancer treatment herein means all current and future treatments to prevent, treat and manage cancer and is not limited to chemotherapy, radiation, immunotherapy, stem cell transplant, surgery, targeted therapy, hormone therapy, pharmacological or non-pharmacological interventions. Embodiments of the present inventions may be used for nausea and vomiting induced by mild, moderate, or highly emetogenic anti-cancer treatment regimens. Embodiments may be used as single or multiple dosage forms or to design a kit or a method to achieve the desired outcome for the patient being treated for cancer. Embodiments may be used or administered immediately, several seconds, hrs, days, or weeks prior to the treatment and/or during the treatment and/or after immediately, several seconds, hrs, days or weeks from initiation of the treatment.
[0149] Regarding PONV, embodiments may be designed in combination with other 5HT3 antagonists, metoclopramide, prochlorperazine, analgesics, anaesthetic agents considering age, type of surgery and patient history.
[0150] In another embodiment, the analgesics is paracetamol.
[0151] In any aspect of the invention, the nausea or vomiting treated is one described herein, in both acute and chronic forms, for example, but not limited to, pregnancy, drug use, alcohol use, motion sickness, gastroenteritis, PCOS, anti-cancer treatment, and surgery, fibromyalgia, digestive disorders (gastritis, gastroparesis, gastroesophageal reflux disease, IBS, celiac disease, gallbladder conditions, pancreas conditions, gallstones, intestinal ischemia, intestinal obstruction, intracranial hematoma, intussusception (in children), irritable bowel syndrome, inflammatory bowel disease (crohn’s, ulcerative colitis), pancreatitis (pancreas inflammation), peptic ulcer, pseudotumor cerebri, pyloric stenosis (in infants), gastroparesis or slow stomach emptying, bowel obstruction, retch, (inflammation of the stomach lining), ulcers, appendicitis, mental health conditions, inner ear conditions (labyrinthitis, vestibular neuritis, meniere’s disease), hormonal changes (thyroid disorders, hyperparathyroidism (overactive parathyroid), hyperthyroidism (overactive thyroid), hypoparathyroidism (underactive parathyroid), , neurological conditions (migraine, increased intracranial pressure due to a mass, blood clot, or haemorrhage, demyelinating disorders, seizure disorders), cardiovascular condition (heart attack, heart failure), medication side effect (antibiotics, antidepressants, OTC pain medication, such as aspirin or ibuprofen, certain supplements, such as iron , opioids, chemotherapy, hormones (e.g., birth control pills), antibiotics, antivirals, anticonvulsants, opioids, nicotine, gastrointestinal medications, cardiovascular medications, medications to treat parkinson’s disease, oral contraceptives, digitalis, narcotics and antibiotics), anxiety disorders, eating disorders, depression, cyclic vomiting syndrome, cancer, stress, general anaesthesia, acute liver failure, anaphylaxis (a severe allergic reaction), anorexia nervosa, appendicitis, benign paroxysmal positional vertigo (bppv), cardiovascular condition, bulimia nervosa, bulimia or other psychological illnesses, cholecystitis food poisoning or stomach flu, coronavirus disease 2019 (COVID- 19), depression (major depressive disorder), diabetic ketoacidosis, dizziness, ear infection (middle ear), inner ear conditions, enlarged spleen (splenomegaly), fever, generalized anxiety disorder, hepatitis, hiatal hernia, hydrocephalus, meningitis, milk allergy , radiation therapy, stem cell transplant, surgery, targeted therapy, hormone therapy, severe pain, toxic hepatitis, concussion or brain injury, coughing, or blocked intestines and illnesses in which the child has a high fever, certain food- borne bacteria, such as salmonella. Preferably, the present invention is used for NV related to pregnancy, drug use, alcohol use, motion sickness, gastroenteritis, PCOS, anti-cancer treatment and surgery.
[0152] A subject in need of treatment is one experiencing or expecting to experience nausea and/or vomiting. The subject may have been diagnosed with NV and/or recommended anti-emetic and/or antinausea treatment by a doctor, pharmacist, nurse, mid-wife, or any health care professional. NV may also be self-diagnosed.
[0153] As used herein, ‘treating’ or ‘treatment’ means reducing, ameliorating, or providing relief from NV before or after its onset. It also includes ameliorating the severity, incidence, progression, or duration of NV experienced by a subject. As compared with an equivalent untreated control, such amelioration or relief is at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, or 100%, as measured by any biochemical or clinical measurement that may be measured by using standard medical methods of evaluating and scoring NV. The benefit to a subject to be treated is either statistically significant or perceptible to the patient or the physician.
[0154] As used herein, the term ‘treatment’ encompasses both disorder-modifying treatment and symptomatic treatment, either of which may be prophylactic, i.e., before the onset of symptoms, in order to prevent, delay or reduce the severity of symptoms, or therapeutic, i.e., after the onset of symptoms, in order to reduce the severity and/or duration of symptoms. The subject also referred to as patient herein may include but are not limited to primates, especially humans, domesticated companion animals such as dogs, cats, horses, and livestock such as cattle, pigs, sheep.
[0155] According to the present invention, compositions comprise one or more excipients required to prepare formulation for therapeutic use. Excipients are extra materials that are added to the active ingredients to prepare a dosage form. Pharmaceutically acceptable excipients including for example and without limitation; one or more binders, adhesives, lubricants, diluents, fillers, coating agent, antiadherent, humectants, preservatives, antioxidants, buffering agents, flavouring agents, bulking agent, colouring agents, sweetening agents, plasticisers, solvent and co-solvent, organic solvents, topical solvents, sorbents, glidants, chelating agents, granulating agent, taste masking agent, thickening agents, disintegrants, plasticisers, solubilizer or solubility enhancer, any carrier oil, coatings, barrier layer formulations, surface active agents, viscosity imparting agents, viscosity increasing agent, stabilising agent, suspending agents, emulsifying agents, viscosity adjusters, gelling agents, sweetening agents, release-delaying agents, skin penetration enhancers, fragrances, dyes/colorants, moisturisers and sustained release materials, film forming agents, conditioning agents, propellants, opacifying agents, pH adjusters, protectants and miscellaneous materials such as adsorbents and buffers in order to prepare a particular composition and other components. Excipients are well known in the art, and the
present invention is not limited in these or this respect. Examples of such components are described in Martindale - The Extra Pharmacopoeia (Pharmaceutical Press, London 1993) and Martin (ed.), Remington's Pharmaceutical Sciences, A. Gennaro, Ed., Mack. Formulations may comprise microcapsules or gelatine-microcapsules, liposomes, albumin microspheres, microemulsions, nanoparticles or nano capsules. The formulation may contain one or more electrolytes. It also extends to formulation changed to reduce the size of the unit dose being administered.
[0156] Pharmaceutically acceptable excipient herein refers to any excipient that does not interfere with the effectiveness of the biological activity of comprised active ingredients and is not contra-indicated, non-toxic and non-teratogenic, i.e., not harmful to a subject and embryo or foetus of a subject.
[0157] Considering intolerance to lactose, gluten, dairy, any specific protein, or any other components, the present invention extends to formulations excluding these excipients.
[0158] Dosage forms may be presented as flavoured dosage, unflavoured, or flavour free. This invention may be presented in any combinations and pharmaceutically acceptable dosage forms. Dosage forms of the present invention may include various forms of release, which include but are not limited to immediate release, extended-release, variable release, controlled release, dissolution- controlled release, sustained release, dual release, delayed-release, long-acting, osmotically controlled release, monolithic dosage forms, multi -particulate forms, and combinations thereof. It can be presented in formulations designed to achieve the shortened and/or extended half-life of the individual ingredients comprised in this invention.
[0159] It is possible that dosage forms may include one or more oral dosage forms as listed here but not limited to tablets, compressed tablets, enteric -coated tablets, controlled release tablets, film-coated tablets, effervescent tablets, reconstitute powders, capsules, soft gelatine capsules, hard gelatine capsules, caplets, multi-layer/dual layer capsule, bi-layer capsule, capsules may encapsulate a powder, liquid, or gel, quick dissolve tablets, multilayer tablets, bi-layer tablets, orally disintegrating tablets, powders, granules, dispersible granules, tablet/capsule combinations, coated core tablets, multi-layered with or without dual release or palletised form. It may be formulated containing ion exchange resins or formulations using responsive polymers.
[0160] Embodiments may be provided, including for example and without any limitation, in the form of lollipops, wafer, bars, sticks, chewable tablets, buccal films, gummies, troches, lozenges, chewable lozenges, beads, bite capsules, mouth soluble or dispersible forms like suckable, eatable, chewable coherent forms, biscuits, cereals, confections, cachets, douches, health bars, patches etc.
[0161] Compounds may be formulated for any appropriate route of administration including for example and without limitation, as oral preparations (solutions, emulsions, suspension, elixirs, syrups, etc.), topical preparations (nasal drops, nebulisers and inhalers, inhalants, pastes, creams and ointments for skin application, gels, lotions, creams, foams, powders, pessaries for vaginal administration etc.), sublingual and buccal administration, rectal administration (suppositories and enemas), ocular, implants, depot implants, ingestible, parental drug administration (intradermal administration, implants, subcutaneous injection, intramuscular injection, intravenous injection, infusions, intramuscular, intraocular, periocular, intraorbital, spinal, intracranial, intrathecal, intrasynovial and intraperitoneal injection), as well as any similar injection or infusion or inhalation technique, solid dosage form and solid modified release form, semi-solid dosage form, sterile or non-sterile dosage forms and deliveries and, novel and advanced dosage forms and including a novel, advanced delivery systems or any combinations thereof.
[0162] The present invention extends to any formulations designed to achieve release of comprised ingredient at a particular location of the subject and/or at any particular rate of release into the subject. The dosage formulation may be modified to achieve release of comprised ingredients at a specific location of the body and/or at any specific rate and/or for any specific time duration
[0163] Typical modes of delivery for topical compositions include applying using the fingers, using a physical applicator such as cloth, tissue, swab, stick or brush, spraying including mist, aerosol or foam spraying, dropper application sprinkling, soaking, and rinsing.
[0164] Compositions may be formulated as inhaled formulations, including sprays, mists, or aerosols and may be delivered via any inhalation methods known to a skilled person in the art. Such methods may include, for example including without limitation, metered-dose inhalers, nebulisers, multi-dose dry powder inhalers or any other conventional or novel inhalation methods.
[0165] The present invention anticipates that the dosage may be supplied in any pharmaceutically acceptable container listed here but not limited to blister packs, composite blister packs, bottles, tubes, canisters, sachets, packets, child-resistant packaging, heat resistance packaging, light resistance packaging, moisture resistance, travelling kit, daily doses packaging, weekly or monthly dose packing, roll on etc. The composition described herein may be presented in individual packaging, day/night combination, composite packaging, packing designed and/or marked to differentiate the unit dose to make it more suitable and/or compliant for any indication and/or any age group and/or any individual subject.
[0166] Embodiments may be combined with other pharmacological or non-pharmacological interventions for the prevention, treatment and management of nausea and vomiting.
[0167] This invention extends to formulations and packaging changed to meet the requirements of particular demographics and/or to obtain regulatory approval from relevant authorities.
[0168] In the context of the unit dose dispensing system, 'daily' herein refers to administering one or more than one dose of the same or different ingredients within the 24-hr period or within the same day. For example, a single daily blister card may include multiple doses to be taken in a 24-hour period.
[0169] Embodiments of the invention may be designed with specific storage requirements in order to preserve comprised constituents. For example, compositions, kits, and methods comprising gingerols and shogaols may be designed with storage requirements to store such embodiments at temperature in the range of -20 to 8 °C.
[0170] Embodiments may be designed with instructions for compounding or preparation prior to administration to the subject. Such instructions may be designed to suit patients, carers, or pharmacists. These embodiments may contain ingredients other than the core ingredients to prepare formulations to achieve the same objective.
[0171] Examples
[0172] The present invention is further explained in the form of following examples. However, it is to be understood that the following examples are merely illustrative and are not to be taken as limitations upon the scope of the invention.
[0173] Example 1
[0174] The tablet of the above composition is prepared by following the steps given below:
Manufacturing of Example 1 and 2:
1. Weigh all the ingredients accurately
2. Pass all the ingredients through 40 # sieve; mix all the ingredients except Colloidal Silicon Dioxide, Talc and Magnesium Stearate by mixing and co-sifting. Continue mixing for 5 minutes
3. Add Colloidal Silicon Dioxide and Talc to the blend of step 3 and mix for 10 minutes.
4. To the blend of step 3 add magnesium stearate and mix further for 3 minutes.
5. Evaluate the lubricated blend for flow properties
6. Compress the blend using 10 mm round concave punches at compression weight of 500 mg
2 at hardness of 5kg / cm
Example 3:
Manufacturing of Example 3 and 4:
1. Weigh all the ingredients accurately
2. Pass all the ingredients through 40 # sieve; mix all the ingredients except Colloidal Silicon Dioxide, Talc and Magnesium Stearate by mixing and co-sifting. Continue mixing for 5 minutes
3. Add Colloidal Silicon Dioxide and Talc to the blend of step 3 and mix for 10 minutes.
4. To the blend of step 3 add magnesium stearate and mix further for 3 minutes.
5. Evaluate the lubricated blend for flow properties
6. Compress the blend using 12 mm round flat punches at compression weight of 700 mg at
2 hardness of 5kg / cm
[0175] The foregoing examples are merely illustrative and are not to be taken as limitations upon the scope of the invention. Various changes and modifications to the disclosed embodiments will be apparent to those skilled in the art. Such changes and modifications may be made without departing from the scope of the invention.
[0176] Embodiments may be designed after establishing the individual needs by means of genetic or biomarks or similar tests.
CITATION LIST
1 Restavit Tablets®. (2006). [online]. Available at: https://www.nps.org.au/assets/medicines/5a2c7827-l 127-4ae9-ac0a-a53300fed848.pdf [Accessed 2 Sep. 2021],
2 Health. (2018). Prescribing medicines in pregnancy database, [online] Therapeutic Goods Administration (TGA). Available at: https://www.tga.gov.au/prescribing-medicines-pregnancy- database.
3 Advancing consumer health through responsible self care. (2018). [online]. Available at: https://www.tga.gov.au/sites/default/files/submissions-received-sedating-antihistamines-asmi.pdf.
4 Taylor, T. (2014). Treatment of nausea and vomiting in pregnancy. Australian Prescriber, 37(2), pp.42-45.
5 Raymond, S.H. (2013). A survey of prescribing for the management of nausea and vomiting in pregnancy in Australasia. Australian and New Zealand Journal of Obstetrics and Gynaecology, 53(4), pp.358-362.
6 www.medicalnewstoday.com. (n.d.). Vitamin B-6: Benefits, dosage, food sources, and deficiency symptoms, [online] Available at: https://www.medicalnewstoday.com/articles/219662.
7 ods.od.nih.gov. (n.d.). Office of Dietary Supplements - Vitamin B6. [online] Available at: https://ods.od.nih.gov/factsheets/vitaminB6-healthprofessional/. [Accessed 2 Sep. 2021].
8 Smpdb.ca. (2021). SMPDB. [online] Available at: https://smpdb.ca/view/SMP0000017.
9 Tanaka, T., Tateno, Y. and Gojobori, T. (2005). Evolution of Vitamin B6 (Pyridoxine) Metabolism by Gain and Loss of Genes. Molecular Biology and Evolution, [online] 22(2), pp.243- 250. Available at: https://academic.oup.eom/mbe/article/22/2/243/963854.
10 Labadarios, D., Rossouw, J.E., McConnell, J.B., Davis, M. and Williams, R. (1977). Vitamin B6 deficiency in chronic liver disease— evidence for increased degradation of pyridoxal-5’ -phosphate. Gut, [online] 18(1), pp.23-27. Available at: https://gut.bmj.eom/content/18/l/23.long [Accessed 13 Aug. 2019
11 Perishable (2018). Vitamin B6 and MTHFR. [online] MTHFRSupport Australia. Available at: https://mthfrsupport.com.au/2018/1 l/vitamin-b6-mthfr/.
12 Gtinalan, E., Yaba, A. and Yilmaz, B. (2018). The Effect of Nutrient Supplementation in Management of Polycystic Ovary Syndrome Associated Metabolic Dysfunctions: A Critical Review. Journal of the Turkish-German Gynecological Association, [online] Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6250088/.
13 www.fxmedicine.com.au. (n.d.). P5P the key to anti-emetic effects of vitamin B6 in morning sickness | FX Medicine, [online] Available at: https://www.fxmedicine.com.au/blog-post/p5p-key- anti-emetic-effects-vitamin-b6-morning-sickness. [Accessed 19 Aug. 2021].
14 Matok, I., Clark, S., Caritis, S., Miodovnik, M., Umans, J.G., Hankins, G., Mattison, D.R. and Koren, G. (2014). Studying the antiemetic effect of vitamin B6 for morning sickness: pyridoxine and pyridoxal are prodrugs. Journal of Clinical Pharmacology, [online] 54(12), pp.1429-1433. Available at: https://pubmed.ncbi.nlm.nih.gov/25052410/. [Accessed 31 Jul. 2020].
15 Kizhakkayil, J. and Sasikumar, B. (2011). Diversity, characterization and utilization of ginger: a review. Plant Genetic Resources, 9(3), pp.464-477.
16 Ginger, (n.d.). [online] . Available at: http://www.agrifs.ir/sites/default/files/Ginger%2C%20The%20Genus%20Zingiber%20%20%7BP. %20N.%20Ravindran%7D%20%5B9780415324687%5D%20%28CRC%20Press%20- %202004%29.pdf.
17 Mao, Q.-Q., Xu, X. Y., Cao, S.-Y., Gan, R.-Y., Corke, H., Beta, T. and Li, H.-B. (2019). Bioactive Compounds and Bioactivities of Ginger (Zingiber officinale Roscoe). Foods, 8(6), p.185.
18 Drying ginger And Preserving 6-gingerol Content, (n.d.). [online] . Available at: http://unsworks.unsw.edu.au/fapi/datastream/unsworks:45630/SQURCE02?view=true.
19 Lete, I. and Alius, J. (2016). The Effectiveness of Ginger in the Prevention of Nausea and Vomiting during Pregnancy and Chemotherapy. Integrative Medicine Insights, [online] 11, p.IMI.S36273. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4818021/.
20 Hsiao, H.-F., Thomas, A., Kay-Smith, C. and Grzeskowiak, L.E. (2021). Pregnant women report being denied medications to treat severe nausea and vomiting of pregnancy or hyperemesis gravidarum - findings from an Australian online survey. The Australian & New Zealand Journal of Obstetrics & Gynaecology, [online] 61(4), pp.616-620. Available at: https://pubmed.ncbi.nlm.nih.gov/33984156/ [Accessed 3 Sep. 2021].
21 Health, A.G.D. of (n.d.). Pharmaceutical Benefits Scheme (PBS) | . [online] www.pbs.gov.au. Available at: https://www.pbs.gov.au/medicine/item/5470X-5857G [Accessed 3 Sep. 2021].
22 ResearchGate. (n.d.). Figure 1: The methionine — homocysteine cycle contains re-methylation... [online] Available at: https://www.researchgate.net/figure/The-methionine-homocysteine-cycle- contains-re-methylation-and-transsulfuration_fig6_286447602 [Accessed 19 Aug. 2021].
23 Cheng, C.-H., Huang, S.-C., Chiang, T.-Y., Wong, Y. and Huang, Y.-C. (2013). Higher Plasma Pyridoxal Phosphate Is Associated with Increased Antioxidant Enzyme Activities in Critically Ill Surgical Patients. BioMed Research International, [online] 2013. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3683421/ [Accessed 28 Aug. 2021].
24 Hsu, C.-C., Cheng, C.-H., Hsu, C.-L., Lee, W.-J., Huang, S.-C. and Huang, Y.-C. (2015). Role of vitamin B6 status on antioxidant defenses, glutathione, and related enzyme activities in mice with homocysteine-induced oxidative stress. Food & Nutrition Research, 59(1), p.25702.
25 ResearchGate. (n.d.). (PDF) Pyridoxine: The “Ba.Six” of use in Nausea and Vomiting of Pregnancy, [online] Available at: https://www.researchgate.net/publication/332971141_Pyridoxine_The_ [Accessed 19 Aug. 2021].
26 ResearchGate. (n.d.). (PDF) The effect of Vitamin B6 on chemotherapy induced nausea and vomiting in pediatric cancer, [online] Available at: https://www.researchgate.net/publication/338408236_The_effect_of_Vitamin_B6_on_chemotherap y_induced_nausea_and_vomiting_in_pediatric_cancer.
27 Veuch, R., Lumeng, L. and Li, T.-K. (n.d.). Vitamin B6 Metabolism in Chronic Alcohol Abuse THE EFFECT OF ETHANOL OXIDATION ON HEPATIC PYRIDOXAL 5 ’-PHOSPHATE METABOLISM, [online] . Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC301849/pdf/jcinvest00169-0160.pdf [Accessed 3 Sep. 2021]
28 Cheng, C.-H., Huang, S.-C., Chiang, T.-Y., Wong, Y. and Huang, Y.-C. (2013). Higher Plasma Pyridoxal Phosphate Is Associated with Increased Antioxidant Enzyme Activities in Critically Ill Surgical Patients. BioMed Research International, [online] 2013. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3683421/.
29 Hsu, C.-C., Cheng, C.-H., Hsu, C.-L., Lee, W.-J., Huang, S.-C. and Huang, Y.-C. (2015). Role of vitamin B6 status on antioxidant defenses, glutathione, and related enzyme activities in mice with homocysteine-induced oxidative stress. Food & Nutrition Research, 59(1), p.25702.
30 Das, S.K. and Vasudevan, D.M. (2007). Alcohol-induced oxidative stress. Life Sciences, [online] 81(3), pp.177-187. Available at: https://www.sciencedirect.com/science/article/abs/pii/S00243205070Q358X.
31 Pertz, H., Lehmann, J., Roth-Ehrang, R. and Elz, S. (2011). Effects of Ginger Constituents on the Gastrointestinal Tract: Role of Cholinergic M3and Serotonergic 5-HT3and 5-HT4Receptors. Planta Medica, 77(10), pp.973-978.
32 Jin, Z., Lee, G., Kim, S., Park, C.-S., Park, Y.S. and Jin, Y.-H. (2014). Ginger and Its Pungent Constituents Non-Competitively Inhibit Serotonin Currents on Visceral Afferent Neurons. The Korean Journal of Physiology & Pharmacology, 18(2), p.149.
33 Lete, I. and Alius, J. (2016). The Effectiveness of Ginger in the Prevention of Nausea and Vomiting during Pregnancy and Chemotherapy. Integrative Medicine Insights, [online] 11, p.IMI.S36273. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4818021/.
34 MacDougall, M.R. and Sharma, S. (2020). Physiology, Chemoreceptor Trigger Zone, [online] PubMed. Available at: https://www.ncbi.nlm.nih. ov/books/NBK537133/.
35 Lete, I. and Alius, J. (2016). The Effectiveness of Ginger in the Prevention of Nausea and Vomiting during Pregnancy and Chemotherapy. Integrative Medicine Insights, [online] 11, p.IMI.S36273. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4818021/.
36 Simon, A., Darcsi, A., Kery, A. and Riethmiiller, E. (2020). Blood-brain barrier permeability study of ginger constituents. Journal of Pharmaceutical and Biomedical Analysis, [online] 177, p.112820. Available at: https://pubmed.ncbi.nlm.nih.gov/31476432/ [Accessed 28 Aug. 2021].
37 Dugasani, S., Pichika, M.R., Nadarajah, V.D., Balijepalli, M.K., Tandra, S. and Korlakunta, J.N. (2010). Comparative antioxidant and anti-inflammatory effects of [6]-gingerol, [8]-gingerol, [10]- gingerol and [6]-shogaol. pubag.nal.usda.gov . [online] Available at: https://pubag.nal.usda.gov/catalog/775366 [Accessed 28 Aug. 2021].
38 Chow, C.M., Leung, A.K. and Hon, K.L. (2010). Acute gastroenteritis: from guidelines to real life. Clinical and experimental gastroenterology, [online] 3, pp.97-112. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108653/.
39 Schaefer, T.S. and Zito, P.M. (2020). Antiemetic Histamine Hl Receptor Blockers . [online] PubMed. Available at: https://www.ncbi.nlm.nih.gov/books/NBK533003/.
40 Kar, S., Krishnan, A., Preetha, K. and Mohankar, A. (2012). A review of antihistamines used during pregnancy. Journal of Pharmacology & Pharmacotherapeutics , [online] 3(2), pp.105-108.
Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3356948/.
41 Kovac, A.L. (2000). Prevention and Treatment of Postoperative Nausea and Vomiting. Drugs, 59(2), pp.213-243.
42 www.sciencedirect.com. (n.d.). Chemotherapy-Induced Nausea and Vomiting - an overview | ScienceDirect Topics, [online] Available at: https://www.sciencedirect.com/topics/neuroscience/chemotherapy-induced-nausea-and-vomiting [Accessed 3 Sep. 2021].
Claims
43
I Claim:
1. A pharmaceutical composition for the prevention, treatment, and management of nausea, vomiting, or combination thereof, comprising:
(a) a ginger extract containing gingerols, shogaols, paradols, or combination thereof,
(b) pyridoxal 5 ’-phosphate, and
(d) excipients required to prepare the pharmaceutical composition.
2. The pharmaceutical composition as claimed in claim 1, wherein the gingerols, shogaols, paradols, or combination thereof present in an amount in the range of 0.5mg to 300mg, the pyridoxal 5 ’-phosphate is present in an amount in a range of Img to 200mg, and the one or more sedative antihistamine(s) is present in an amount in a range of 0.5mg to 200mg.
3. The pharmaceutical composition as claimed in claim 1 or 2, wherein the gingerol is selected from the group consisting of (6)-gingerol, (8)-gingerol, (lO)-gingerol, (6)- gingerdione, (6)-gingerdiol, (6)-gingerdiol diacetate, (6)-ginger sulphonic acid, 6)- demethoxygingerol, (6)-methylgingerol, or combination thereof; the paradol is (6)-paradol, (8)-paradol, (lO)-paradol, or combination thereof; and the shogaol is (6)-demethoxyshogaol, (6)-shogaol, (8)-shogaol, (10) shogaol, (6)-methylshogaol, (6)-hydroxyshogaol, (6)- dehydroshogaol, or combination thereof and one or more pharmaceutically acceptable salt(s), metabolite(s), analog(s), polymorph(s), isomer(s), prodrug(s), solvate(s), hydrate(s), or derivative(s) thereof.
4. The pharmaceutical composition as claimed in claim 1 or 2, further comprise pyridoxal, pyridoxamine, pyridoxine 5' phosphate and pyridoxamine 5' phosphate.
5. The pharmaceutical composition as claimed in claim 1 or 2, wherein one or more sedative antihistamine is short-acting, long-acting, intermediate-acting, or combination thereof.
6. The pharmaceutical composition as claimed in any one of the claims 1, 2, and 5, wherein the one or more sedative antihistamine is selected from the group consisting of doxylamine and salt thereof, dexchlorpheniramine and salt thereof, diphenhydramine and salt thereof, dimenhydrinate and salt thereof, chlorpheniramine and salt thereof, brompheniramine and salt thereof, pheniramine and salt thereof, hydroxyzine and salt thereof, cyproheptadine and salt thereof, carbinoxamine and salt thereof, pyrilamine and salt thereof, tripelennamine and salt thereof, phenindamine and salt thereof, trimeprazine, and salt thereof, cyclizine and salt thereof, promethazine and salt thereof, phenyltoloxamine and salt thereof, cyproheptadine
44 of, alimemazine and salt thereof, clemastine and salt thereof, ketotifen and salt thereof, mepyramine and salt thereof, antazoline and salt thereof, orphenadrine and salt thereof, bromazine and salt thereof, dexbrompheniramine and salt thereof, tripolidine and salt thereof, chlorcyclizine and salt thereof, hydroxyzine and salt thereof, meclizine and salt thereof, and azatadine and salt thereof.
7. The pharmaceutical composition as claimed in any one of the claims 1 to 6, wherein the salt is selected from the group consisting of succinate, maleate, esters, amines, hydrochloride, phosphate, calcium phosphate, or dihydrochloride.
8. A pharmaceutical composition for the prevention, treatment, and management of nausea, vomiting, or combination thereof comprising of:
(a) a ginger extract containing gingerols, shogaols, paradols, or combination thereof,
(b) pyridoxal 5 ’-phosphate, pyridoxal, pyridoxamine, pyridoxine 5' phosphate and pyridoxamine 5' phosphate, or combination thereof,
(c) one or more sedative antihistamine(s),
(d) (i) pyridoxine hydrochloride, (ii) a non-standardised form of ginger, (iii) Levomepromazine, or combination thereof and
(e) excipients required to prepare a pharmaceutical composition.
9. The pharmaceutical composition as claimed in any one of the claims 1 to 8, wherein the composition further comprises other ingredients such as caffeine, antioxidants (e.g. glutathione, reduced glutathione), one or more forms of iron, vitamin A (e.g., retinol acetate), one or more forms of vitamin B12, vitamin B3, alpha-lipoic acid (R or S form), one or more forms of vitamin C, alpha tocotrienol, coenzyme Q10 (activated or inactivated), ubiquinol, zinc, selenium, magnesium citrate, magnesium glycinate, and magnesium chelates, Hl antagonists; H2 antagonists; proton-pump inhibitors, analgesics (paracetamol); flavin mononucleotide (FMN, also known as riboflavin-5-phosphate or R5P), metabolites of riboflavin; folinic acid; 5-MTHF; folic acid; probiotics; or combination thereof.
10. The composition as claimed in any one of the claims 1 to 9, wherein lactose, gluten or dairy-derived excipients are excluded.
11. The pharmaceutical composition as claimed in any one of the claims 1 to 10, wherein one, more or all pharmaceutical composition(s) are modified to release the ingredients at a specific location of the body and/or at a specific rate and/or for a specific time duration.
45 he prevention, treatment, and management of nausea, vomiting, or combination thereof comprising:
(i) a first pharmaceutical composition as claimed in any one of the claims 1 to 11 provided that the first composition is with one or more sedative antihistamine(s); and
(ii) a second pharmaceutical composition as claimed in any one of the claims 1 to 11 provided that the second composition is without one or more sedative antihistamine(s) or in an amount that is less likely to cause the sedation; wherein the kit is adapted to allow access to each pharmaceutical composition at the same or different times.
13. The kit as claimed in claim 12, wherein the kit is designed or presented with the indicia distinguishing the first and second pharmaceutical composition from each other, dosage instructions for a specific medical condition, instructions for coordinating the administration of each pharmaceutical composition wherein;
(i) the first pharmaceutical composition is to administer during a particular time and/or at specific time interval(s) of the day or over 24 hrs period or an event, when sedation or sleep is desirable or not contraindicated, or
(ii) the first or second pharmaceutical composition is to administer during a particular time and/or at specific time interval(s) of the day or over 24 hrs period or an event, when sedation or sleep is not desirable or not expected or contraindicated, wherein the container that incorporates the kit includes the indicia, the instructions, and a plurality of first and second pharmaceutical compositions, wherein the kit is designed for ‘day and night’ use and/or is presented as a kit comprising ‘drowsy’ and/or ‘non-drowsy’ pharmaceutical compositions, wherein the first pharmaceutical composition is administered with or without the second pharmaceutical composition, wherein the kit is designed or presented to provide access to each pharmaceutical composition, the indicia distinguishing each pharmaceutical composition from each other, dosage instructions related to a specific medical condition, instructions for coordinating the administration of each pharmaceutical composition for the duration of one to four weeks or a month.
14. The pharmaceutical composition and the kit according to any one of the preceding claims, wherein each pharmaceutical composition present therein comprises a different sedative
and/or dose of each sedative antihistamine is different in each pharmaceutical composition present therein.
15. The pharmaceutical composition and the kit according to any one of the preceding claims wherein levomepromazine is added, or one, more or all sedative antihistamine(s) are replaced with levomepromazine.
16. The pharmaceutical composition and the kit according to any one of the preceding claims, wherein the pharmaceutical composition or kit is prepared in a compounding pharmacy or in a facility approved by the relevant authority of the local jurisdiction to manufacture therapeutic preparation.
17. A method of prevention, treatment, and management of nausea, vomiting, or combination thereof comprising administering the therapeutically effective amount of the pharmaceutical composition and kit as claimed in any one of the claims 1 to 16 to a subject in need thereof.
18. A pharmaceutical composition and kit as claimed in any one of the claims 1 to 16 for use in the manufacture of medicament for the prevention, treatment, and management of nausea, vomiting, or combination thereof.
19. Use of the pharmaceutical composition and kit as claimed in any one of the claims 1 to 16 for the prevention, treatment, and management of nausea, vomiting, or combination thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2021225255A AU2021225255B1 (en) | 2021-09-03 | 2021-09-03 | Compositions, kits, and methods to provide synergistic and/or additive effects from comprised ingredients for the prevention, treatment and management of nausea and vomiting. |
AU2021225255 | 2021-09-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023031779A1 true WO2023031779A1 (en) | 2023-03-09 |
Family
ID=81943726
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2022/058102 WO2023031779A1 (en) | 2021-09-03 | 2022-08-30 | Compositions, kits, and methods to provide synergistic and/or additive effects from comprised ingredients for the prevention, treatment and management of nausea and vomiting |
PCT/IB2022/058241 WO2023031860A1 (en) | 2021-09-03 | 2022-09-02 | Compositions, kits, and methods to provide synergistic and/or additive effects from comprised ingredients for the prevention, treatment and management of nausea and vomiting. |
PCT/IB2022/058243 WO2023031861A1 (en) | 2021-09-03 | 2022-09-02 | Compositions, kits, and methods for treatment of nausea and vomiting |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2022/058241 WO2023031860A1 (en) | 2021-09-03 | 2022-09-02 | Compositions, kits, and methods to provide synergistic and/or additive effects from comprised ingredients for the prevention, treatment and management of nausea and vomiting. |
PCT/IB2022/058243 WO2023031861A1 (en) | 2021-09-03 | 2022-09-02 | Compositions, kits, and methods for treatment of nausea and vomiting |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2021225255B1 (en) |
WO (3) | WO2023031779A1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070048367A1 (en) * | 2005-08-31 | 2007-03-01 | Mom Enterprises, Inc. | Herbal composition for treating morning sickness |
US20110028436A1 (en) * | 2008-03-25 | 2011-02-03 | Sarah Steinberg Greenwald | Oral combination of vitamins |
WO2015080623A1 (en) * | 2013-11-26 | 2015-06-04 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Agent for the prevention of nausea and vomiting during pregnancy |
WO2021144625A1 (en) * | 2020-01-18 | 2021-07-22 | Maneesh Pharmaceuticals Ltd | The oral synergistic composition and its process for the preparation |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2350195C (en) * | 2000-12-20 | 2003-06-10 | Duchesnay Inc. | Rapid onset formulation of pyridoxine hydrochloride and doxylamine succinate |
US7670612B2 (en) * | 2002-04-10 | 2010-03-02 | Innercap Technologies, Inc. | Multi-phase, multi-compartment capsular delivery apparatus and methods for using same |
US7067150B2 (en) * | 2002-04-16 | 2006-06-27 | Scepter Holdings, Inc. | Delivery systems for functional ingredients |
CN1887340A (en) * | 2005-06-28 | 2007-01-03 | 陈依侬 | Cinesia treating medicine composition |
WO2008070783A2 (en) * | 2006-12-07 | 2008-06-12 | Herbalscience Singapore Pte. Ltd. | Compositions and methods comprising zingiber species |
MX2010010275A (en) * | 2008-03-17 | 2010-09-30 | Procter & Gamble | User-customizable dosing system. |
ES2809713T3 (en) * | 2012-02-22 | 2021-03-05 | Duchesnay Inc | Formulation of doxylamine and pyridoxine and / or metabolites or salts of these |
US20140147519A1 (en) * | 2012-11-26 | 2014-05-29 | Larry A. MCPHAIL | Migraine Treatment |
US20190160138A1 (en) * | 2016-01-19 | 2019-05-30 | The Remedy Lab, Llc | Dietary supplement for gluten reaction |
JP2018076312A (en) * | 2016-11-02 | 2018-05-17 | 第一三共ヘルスケア株式会社 | Pharmaceutical composition containing acetaminophen, isopropylantipyrine and ginger-derived components |
CN108114258A (en) * | 2018-01-24 | 2018-06-05 | 任云超 | A kind of drug for treating tinea pedis |
EP3682901A1 (en) * | 2019-01-21 | 2020-07-22 | Omya International AG | High performance excipient comprising co-processed microcrystalline cellulose and surface-reacted calcium carbonate |
-
2021
- 2021-09-03 AU AU2021225255A patent/AU2021225255B1/en active Active
-
2022
- 2022-08-30 WO PCT/IB2022/058102 patent/WO2023031779A1/en unknown
- 2022-09-02 WO PCT/IB2022/058241 patent/WO2023031860A1/en unknown
- 2022-09-02 WO PCT/IB2022/058243 patent/WO2023031861A1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070048367A1 (en) * | 2005-08-31 | 2007-03-01 | Mom Enterprises, Inc. | Herbal composition for treating morning sickness |
US20110028436A1 (en) * | 2008-03-25 | 2011-02-03 | Sarah Steinberg Greenwald | Oral combination of vitamins |
WO2015080623A1 (en) * | 2013-11-26 | 2015-06-04 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Agent for the prevention of nausea and vomiting during pregnancy |
WO2021144625A1 (en) * | 2020-01-18 | 2021-07-22 | Maneesh Pharmaceuticals Ltd | The oral synergistic composition and its process for the preparation |
Non-Patent Citations (1)
Title |
---|
NIEBYL, JENNIFER R: "Nausea and vomiting in pregnancy", THE NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, US, vol. 363, no. 16, 14 October 2010 (2010-10-14), US , pages 1544 - 1550, XP009544155, ISSN: 0028-4793, DOI: 10.1056/NEJMcp1003896 * |
Also Published As
Publication number | Publication date |
---|---|
WO2023031861A1 (en) | 2023-03-09 |
AU2021225255B1 (en) | 2022-06-16 |
WO2023031860A1 (en) | 2023-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6665094B2 (en) | Compositions and methods for reducing major adverse cardiovascular events | |
TW201615221A (en) | The new indication of the anti-inflammatory drugs | |
JP6511492B2 (en) | Treatment of symptoms related to female gastroparesis | |
KR20220042241A (en) | Methods of treating overweight and obesity | |
AU2011203867A1 (en) | Methods of providing weight loss therapy in patients with major depression | |
US20230094778A1 (en) | Treatment of moderate and severe gastroparesis | |
US20090306119A1 (en) | Non-Codeine Opioid Analgesic Process And Formulations | |
US20220151960A1 (en) | Treatment of symptoms associated with female gastroparesis | |
Hamilton et al. | Tarascon pharmacopoeia | |
MXPA00003385A (en) | Serotonin containing formulation for oral administration and method of use. | |
WO2023031779A1 (en) | Compositions, kits, and methods to provide synergistic and/or additive effects from comprised ingredients for the prevention, treatment and management of nausea and vomiting | |
US20060128688A1 (en) | Asenapine for the treatment of schizophrenia in a patient with overweight or predisposition for overweight | |
TW200821296A (en) | Use of sertindole for the preventive treatment of suicidal behaviour | |
FAAEM | Tarascon Pharmacopoeia 2017 professional desk reference edition | |
AU2016218950C1 (en) | Analgesic formulation | |
CA3181629A1 (en) | Rabeximod in the treatment of rheumatoid arthritis | |
US20040019107A1 (en) | Homeopathic drug composition and methods of use thereof | |
Cox | Pharmacology interventions for symptom management | |
Rizvi et al. | Timothy grass pollen allergen extract (Grastek) for allergic rhinitis | |
JP2004210750A (en) | Biorhythm application kit | |
Hamilton | Tarascon Pharmacopoeia 2011 Library Edition | |
Tsu et al. | Geriatric Pharmacology Case Series: Direct Oral Anticoagulants for Older People With Cancer | |
TW201306831A (en) | Compositions and methods for treating myelodysplastic syndrome | |
Be | TYLE X |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22863743 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |